[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fQmW8_nHiseqcK-EfFrBn6PSWyxo1XqNimkbgdsyASZg":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":33,"phaseBuckets":49,"rows":56},"Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University",[4],161,false,9,6,10932,7,54,[14,17,19,22,24,26,29,31],{"name":15,"count":16},"Prostate Cancer",11,{"name":18,"count":9},"Breast Cancer",{"name":20,"count":21},"Head and Neck Cancer",5,{"name":23,"count":21},"Malignant Neoplasm",{"name":25,"count":21},"Breast Carcinoma",{"name":27,"count":28},"Non-Hodgkin's Lymphoma",4,{"name":30,"count":28},"Recurrent Adult Acute Myeloid Leukemia",{"name":32,"count":28},"Chronic Lymphocytic Leukemia",[34,39,44],{"nctId":35,"briefTitle":36,"date":37,"intervention":38},"NCT03796884","Linaclotide in Treating Patients With Stages 0-3 Colorectal Cancer","2026-06-30","Linaclotide",{"nctId":40,"briefTitle":41,"date":42,"intervention":43},"NCT03198026","Obinutuzumab and Ibrutinib as Front Line Therapy in Treating Patients With Indolent Non-Hodgkin's Lymphomas","2026-09-11","Ibrutinib",{"nctId":45,"briefTitle":46,"date":47,"intervention":48},"NCT02068586","Sunitinib Malate or Valproic Acid in Preventing Metastasis in Patients With High-Risk Uveal Melanoma","2026-12-31","Sunitinib",[50,51,52,53,54,55],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[57,110,128,146,164,204,222,253,278,305,464,579,654,706,766,807,863,889,911,963,1004,1026,1064,1086,1125,1172,1209,1237,1264,1282,1308,1326,1352,1379,1409,1427,1445,1463,1481,1505,1523,1541,1564,1582,1600,1623,1641,1659,1681,1699,1717,1735,1759,1783,1812,1830,1856,1885,1903,1921,1948,1966,1984,2008,2035,2053,2071,2089,2107,2125,2143,2161,2185,2212,2239,2257,2275,2309,2344,2380,2398,2416,2440,2467,2485,2510,2528,2546,2569,2592,2616,2640,2668,2686,2704,2730,2756,2774,2792,2814,2832,2856,2874,2892,2910,2943,2968,3004,3028,3056,3079,3097,3129,3147,3165,3183,3207,3225,3320,3399,3469,3511,3559,3593,3635,3661,3692,3725,3747,3769,3792,3810,3837,3855,3873,3891,3917,3935,3953,3971,3989,4007,4025],{"intervention":48,"totalTrials":58,"cells":59},2,{"EARLY_PHASE1":60,"PHASE1":63,"PHASE2":79,"PHASE3":104,"PHASE4":106,"NA":108},{"trials":61,"activeCount":62},[],0,{"trials":64,"activeCount":62},[65],{"nctId":66,"briefTitle":67,"status":68,"phases":69,"primaryCompletion":70,"completion":70,"start":71,"enrollment":72,"conditions":73,"interventions":78},"NCT00437372","Phase IB Study Using Sunitinib Plus Radiation Therapy for Cancer Patients","COMPLETED",[51],"2010-12","2007-03",39,[74,20,75,76,77],"Cancer","Pelvic Cancer","Nervous System Neoplasms","Thoracic Neoplasms",[48],{"trials":80,"activeCount":103,"soonestReadout":47},[81],{"nctId":45,"briefTitle":46,"status":82,"phases":83,"primaryCompletion":47,"completion":47,"start":84,"enrollment":85,"conditions":86,"interventions":99},"ACTIVE_NOT_RECRUITING",[52],"2014-11-19",210,[87,88,89,90,91,92,93,94,95,96,97,98],"Ciliary Body and Choroid Melanoma, Medium\u002FLarge Size","Ciliary Body and Choroid Melanoma, Small Size","Iris Melanoma","Stage I Intraocular Melanoma","Stage IIA Intraocular Melanoma","Stage IIB Intraocular Melanoma","Stage IIIA Intraocular Melanoma","Stage IIIB Intraocular Melanoma","Stage IIIC Intraocular Melanoma","Stage I Uveal Melanoma AJCC V7","Stage II Uveal Melanoma AJCC V7","Stage III Uveal Melanoma AJCC V7",[48,100,101,102],"Valproic Acid","Sunitinib Malate","Sunitinib Malate + Valproic Acid",1,{"trials":105,"activeCount":62},[],{"trials":107,"activeCount":62},[],{"trials":109,"activeCount":62},[],{"intervention":100,"totalTrials":103,"cells":111},{"EARLY_PHASE1":112,"PHASE1":114,"PHASE2":116,"PHASE3":122,"PHASE4":124,"NA":126},{"trials":113,"activeCount":62},[],{"trials":115,"activeCount":62},[],{"trials":117,"activeCount":103,"soonestReadout":47},[118],{"nctId":45,"briefTitle":46,"status":82,"phases":119,"primaryCompletion":47,"completion":47,"start":84,"enrollment":85,"conditions":120,"interventions":121},[52],[87,88,89,90,91,92,93,94,95,96,97,98],[48,100,101,102],{"trials":123,"activeCount":62},[],{"trials":125,"activeCount":62},[],{"trials":127,"activeCount":62},[],{"intervention":101,"totalTrials":103,"cells":129},{"EARLY_PHASE1":130,"PHASE1":132,"PHASE2":134,"PHASE3":140,"PHASE4":142,"NA":144},{"trials":131,"activeCount":62},[],{"trials":133,"activeCount":62},[],{"trials":135,"activeCount":103,"soonestReadout":47},[136],{"nctId":45,"briefTitle":46,"status":82,"phases":137,"primaryCompletion":47,"completion":47,"start":84,"enrollment":85,"conditions":138,"interventions":139},[52],[87,88,89,90,91,92,93,94,95,96,97,98],[48,100,101,102],{"trials":141,"activeCount":62},[],{"trials":143,"activeCount":62},[],{"trials":145,"activeCount":62},[],{"intervention":102,"totalTrials":103,"cells":147},{"EARLY_PHASE1":148,"PHASE1":150,"PHASE2":152,"PHASE3":158,"PHASE4":160,"NA":162},{"trials":149,"activeCount":62},[],{"trials":151,"activeCount":62},[],{"trials":153,"activeCount":103,"soonestReadout":47},[154],{"nctId":45,"briefTitle":46,"status":82,"phases":155,"primaryCompletion":47,"completion":47,"start":84,"enrollment":85,"conditions":156,"interventions":157},[52],[87,88,89,90,91,92,93,94,95,96,97,98],[48,100,101,102],{"trials":159,"activeCount":62},[],{"trials":161,"activeCount":62},[],{"trials":163,"activeCount":62},[],{"intervention":43,"totalTrials":103,"cells":165},{"EARLY_PHASE1":166,"PHASE1":168,"PHASE2":170,"PHASE3":198,"PHASE4":200,"NA":202},{"trials":167,"activeCount":62},[],{"trials":169,"activeCount":62},[],{"trials":171,"activeCount":103,"soonestReadout":42},[172],{"nctId":40,"briefTitle":41,"status":82,"phases":173,"primaryCompletion":42,"completion":174,"start":175,"enrollment":176,"conditions":177,"interventions":196},[52],"2032-02-20","2018-02-20",30,[27,178,179,180,181,182,183,184,185,186,187,188,189,190,191,192,193,194,195],"Ann Arbor Stage II Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue","Ann Arbor Stage II Follicular Lymphoma","Ann Arbor Stage II Nodal Marginal Zone Lymphoma","Ann Abor Stage III B-Cell Non-Hodgkin Lymphoma","Ann Arbor Stage III Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue","Ann Arbor Stage III Follicular Lymphoma","Ann Arbor Stage III Nodal Marginal Zone Lymphoma","Ann Arbor Stage IV B-Cell Non-Hodgkin Lymphoma","Ann Arbor Stage IV Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue","Ann Arbor Stage IV Follicular Lymphoma","Ann Arbor Stage IV Nodal Marginal Zone Lymphoma","Grade 1 Follicular Lymphoma","Grade 2 Follicular Lymphoma","Grade 3a Follicular Lymphoma","Indolent Non-hodgkin Lymphoma","Stage II Splenic Marginal Zone Lymphoma","Stage III Splenic Marginal Zone Lymphoma","Stage IV Splenic Marginal Zone Lymphoma",[43,197],"Obinutuzumab",{"trials":199,"activeCount":62},[],{"trials":201,"activeCount":62},[],{"trials":203,"activeCount":62},[],{"intervention":197,"totalTrials":103,"cells":205},{"EARLY_PHASE1":206,"PHASE1":208,"PHASE2":210,"PHASE3":216,"PHASE4":218,"NA":220},{"trials":207,"activeCount":62},[],{"trials":209,"activeCount":62},[],{"trials":211,"activeCount":103,"soonestReadout":42},[212],{"nctId":40,"briefTitle":41,"status":82,"phases":213,"primaryCompletion":42,"completion":174,"start":175,"enrollment":176,"conditions":214,"interventions":215},[52],[27,178,179,180,181,182,183,184,185,186,187,188,189,190,191,192,193,194,195],[43,197],{"trials":217,"activeCount":62},[],{"trials":219,"activeCount":62},[],{"trials":221,"activeCount":62},[],{"intervention":38,"totalTrials":103,"cells":223},{"EARLY_PHASE1":224,"PHASE1":226,"PHASE2":228,"PHASE3":247,"PHASE4":249,"NA":251},{"trials":225,"activeCount":62},[],{"trials":227,"activeCount":62},[],{"trials":229,"activeCount":103,"soonestReadout":37},[230],{"nctId":35,"briefTitle":36,"status":82,"phases":231,"primaryCompletion":37,"completion":37,"start":232,"enrollment":233,"conditions":234,"interventions":246},[52],"2019-10-30",230,[235,236,237,238,239,240,241,242,243,244,245],"Colorectal Adenoma","Stage 0 Colorectal Cancer AJCC v8","Stage I Colorectal Cancer AJCC v8","Stage II Colorectal Cancer AJCC v8","Stage IIA Colorectal Cancer AJCC v8","Stage IIB Colorectal Cancer AJCC v8","Stage IIC Colorectal Cancer AJCC v8","Stage III Colorectal Cancer AJCC v8","Stage IIIA Colorectal Cancer AJCC v8","Stage IIIB Colorectal Cancer AJCC v8","Stage IIIC Colorectal Cancer AJCC v8",[38],{"trials":248,"activeCount":62},[],{"trials":250,"activeCount":62},[],{"trials":252,"activeCount":62},[],{"intervention":254,"totalTrials":103,"cells":255},"dutasteride",{"EARLY_PHASE1":256,"PHASE1":258,"PHASE2":260,"PHASE3":262,"PHASE4":274,"NA":276},{"trials":257,"activeCount":62},[],{"trials":259,"activeCount":62},[],{"trials":261,"activeCount":62},[],{"trials":263,"activeCount":62},[264],{"nctId":265,"briefTitle":266,"status":68,"phases":267,"primaryCompletion":268,"completion":269,"start":270,"enrollment":271,"conditions":272,"interventions":273},"NCT00398281","Dutasteride Followed By Ultrasound-Guided Biopsy in Finding Prostate Cancer",[53],"2010-07","2012-09","2006-11",450,[15],[254],{"trials":275,"activeCount":62},[],{"trials":277,"activeCount":62},[],{"intervention":279,"totalTrials":103,"cells":280},"Ultrasound contrast agent",{"EARLY_PHASE1":281,"PHASE1":283,"PHASE2":285,"PHASE3":287,"PHASE4":301,"NA":303},{"trials":282,"activeCount":62},[],{"trials":284,"activeCount":62},[],{"trials":286,"activeCount":62},[],{"trials":288,"activeCount":62},[289],{"nctId":290,"briefTitle":291,"status":68,"phases":292,"primaryCompletion":293,"completion":294,"start":295,"enrollment":296,"conditions":297,"interventions":300},"NCT02764801","Contrast-enhanced Ultrasound Evaluation of Chemoembolization",[53],"2021-12","2023-02-01","2016-04",131,[298,299],"Hepatocellular Carcinoma","Chemoembolization, Therapeutic",[279],{"trials":302,"activeCount":62},[],{"trials":304,"activeCount":62},[],{"intervention":306,"totalTrials":11,"cells":307},"Donor Lymphocyte",{"EARLY_PHASE1":308,"PHASE1":310,"PHASE2":312,"PHASE3":458,"PHASE4":460,"NA":462},{"trials":309,"activeCount":62},[],{"trials":311,"activeCount":62},[],{"trials":313,"activeCount":62},[314,328,350,408,419,434,443],{"nctId":315,"briefTitle":316,"status":68,"phases":317,"primaryCompletion":318,"completion":319,"start":320,"enrollment":321,"conditions":322,"interventions":324},"NCT01341301","Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Malignancies",[52],"2013-11-04","2014-08-07","2010-05",25,[323],"Hematologic Malignancy",[306,325,326,327],"Cyclophosphamide","Tacrolimus","Mycophenolate mofetil",{"nctId":329,"briefTitle":330,"status":331,"phases":332,"primaryCompletion":333,"completion":334,"start":335,"enrollment":28,"conditions":336,"interventions":347},"NCT01532635","A Two-Step Approach to Bone Marrow Transplant Using Cells From Two Partially-Matched Relatives","TERMINATED",[52],"2013-02","2013-05","2012-03",[323,337,338,339,340,341,32,342,343,344,345,346],"Leukemia","Acute Lymphoblastic Leukemia","ALL","Acute Myelogenous Leukemia","AML","CLL","Lymphoma","Hodgkin's Lymphoma","Non-hodgkin's Lymphoma","Myeloma",[306,325,326,348,349],"Mycophenolate Mofetil","Hematopoietic Stem Cell Transplant",{"nctId":351,"briefTitle":352,"status":68,"phases":353,"primaryCompletion":354,"completion":355,"start":356,"enrollment":357,"conditions":358,"interventions":405},"NCT01384513","A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies",[52],"2020-11-13","2022-11-16","2011-08-04",40,[359,360,361,362,363,364,365,366,367,368,369,370,371,372,373,374,375,376,377,378,379,380,381,382,383,384,30,385,386,387,388,389,390,391,392,393,394,395,396,397,398,399,400,401,402,403,404],"Adult Acute Lymphoblastic Leukemia in Remission","Adult Acute Myeloid Leukemia in Remission","Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities","Adult Acute Myeloid Leukemia With Del(5q)","Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)","Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)","Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)","Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)","Adult Nasal Type Extranodal NK\u002FT-cell Lymphoma","Aplastic Anemia","Childhood Acute Lymphoblastic Leukemia in Remission","Childhood Acute Myeloid Leukemia in Remission","Childhood Myelodysplastic Syndromes","Chronic Eosinophilic Leukemia","Chronic Myelomonocytic Leukemia","Chronic Neutrophilic Leukemia","Essential Thrombocythemia","Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue","Juvenile Myelomonocytic Leukemia","Mastocytosis","Myelodysplastic\u002FMyeloproliferative Neoplasm, Unclassifiable","Nodal Marginal Zone B-cell Lymphoma","Polycythemia Vera","Previously Treated Myelodysplastic Syndromes","Primary Myelofibrosis","Recurrent Adult Acute Lymphoblastic Leukemia","Recurrent Adult Diffuse Small Cleaved Cell Lymphoma","Recurrent Adult Grade III Lymphomatoid Granulomatosis","Recurrent Adult Hodgkin Lymphoma","Recurrent Childhood Acute Lymphoblastic Leukemia","Recurrent Childhood Acute Myeloid Leukemia","Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma","Recurrent Grade 1 Follicular Lymphoma","Recurrent Grade 2 Follicular Lymphoma","Recurrent Marginal Zone Lymphoma","Recurrent Mycosis Fungoides\u002FSezary Syndrome","Recurrent Small Lymphocytic Lymphoma","Recurrent\u002FRefractory Childhood Hodgkin Lymphoma","Refractory Anemia","Refractory Anemia With Ringed Sideroblasts","Refractory Hairy Cell Leukemia","Refractory Multiple Myeloma","Secondary Myelodysplastic Syndromes","Splenic Marginal Zone Lymphoma","T-cell Large Granular Lymphocyte Leukemia","Waldenström Macroglobulinemia",[406,407,306,325,326,327],"Fludarabine","Busulfan",{"nctId":409,"briefTitle":410,"status":68,"phases":411,"primaryCompletion":412,"completion":413,"start":414,"enrollment":415,"conditions":416,"interventions":418},"NCT00429143","A Two-Step Approach to Bone Marrow Transplant Using Cells From A Partially-Matched Relative",[51,52],"2009-08","2010-06","2006-01",27,[417],"Hematologic Malignancies",[306,325,326,348,349],{"nctId":420,"briefTitle":421,"status":68,"phases":422,"primaryCompletion":334,"completion":423,"start":268,"enrollment":424,"conditions":425,"interventions":433},"NCT01350245","Bone Marrow Transplantation of Patients in Remission Using Partially Matched Relative Donor",[52],"2014-05",28,[426,427,428,429,430,32,431,343,432,368],"Acute Myeloid Leukemia","Myelodysplastic Syndromes","Biphenotypic Leukemia","Acute Lymphocytic Leukemia","Chronic Myeloid Leukemia","Plasma Cell Neoplasms","Hodgkin's Disease",[306,325,348,326],{"nctId":435,"briefTitle":436,"status":68,"phases":437,"primaryCompletion":438,"completion":438,"start":318,"enrollment":439,"conditions":440,"interventions":442},"NCT01982682","Allogeneic Hematopoietic Stem Cell Transplantation for High-Risk Hematologic Malignancies Using One Haploidentical Donor",[52],"2017-03-27",41,[441],"Hematopoietic\u002FLymphoid Cancer",[306,325,327],{"nctId":444,"briefTitle":445,"status":331,"phases":446,"primaryCompletion":447,"completion":448,"start":449,"enrollment":450,"conditions":451,"interventions":455},"NCT01350258","Bone Marrow Transplant Using a Reduced Intensity Regimen That is Given in Two Steps",[51,52],"2012-05","2012-08","2011-04",8,[417,452,453,344,27,346,454],"Acute Leukemia","Myelodysplastic Syndromes (MDS) Other Than RA or RARS Subtypes","Chronic Myelogenous (or Myeloid) Leukemia (CML) Resistant to STI Therapy",[406,456,306,457],"Thiotepa","Melphalan",{"trials":459,"activeCount":62},[],{"trials":461,"activeCount":62},[],{"trials":463,"activeCount":62},[],{"intervention":465,"totalTrials":9,"cells":466},"Nivolumab",{"EARLY_PHASE1":467,"PHASE1":492,"PHASE2":494,"PHASE3":573,"PHASE4":575,"NA":577},{"trials":468,"activeCount":62},[469,481],{"nctId":470,"briefTitle":471,"status":68,"phases":472,"primaryCompletion":473,"completion":355,"start":474,"enrollment":475,"conditions":476,"interventions":479},"NCT03162731","Nivolumab, Ipilimumab, and Radiation Therapy in Treating Patients With Stage III-IVB Head and Neck Cancer",[50],"2020-09-27","2017-05-11",24,[477,478],"Larynx","Lip, Oral Cavity and Pharynx",[465,480],"Ipilimumab",{"nctId":482,"briefTitle":483,"status":68,"phases":484,"primaryCompletion":485,"completion":486,"start":487,"enrollment":488,"conditions":489,"interventions":490},"NCT03238365","Window of Opportunity Trial of Nivolumab and Tadalafil in Patients With Squamous Cell Carcinoma of the Head and Neck",[50],"2019-07-30","2022-09-08","2017-08-10",50,[478,477],[465,491],"Tadalafil",{"trials":493,"activeCount":62},[],{"trials":495,"activeCount":62},[496,506,527,540],{"nctId":497,"briefTitle":498,"status":68,"phases":499,"primaryCompletion":500,"completion":500,"start":501,"enrollment":502,"conditions":503,"interventions":505},"NCT03405155","Nivolumab in Treating Patients With Stage IIB-IIC Melanoma That Can Be Removed by Surgery",[52],"2025-12-15","2018-01-17",26,[504],"Melanoma (Skin)",[465],{"nctId":507,"briefTitle":508,"status":331,"phases":509,"primaryCompletion":510,"completion":511,"start":512,"enrollment":513,"conditions":514,"interventions":523},"NCT03366766","Nivolumab Plus Cisplatin\u002FPemetrexed or Cisplatin\u002FGemcitabine as Induction in Resectable Non-Small Cell Lung Cancer",[52],"2020-12-06","2023-02-08","2017-12-20",14,[515,516,517,518,519,520,521,522],"Non-Squamous Non-Small Cell Lung Carcinoma","Stage I Non-Small Cell Lung Cancer","Stage IA Non-Small Cell Lung Carcinoma","Stage IB Non-Small Cell Lung Carcinoma","Stage II Non-Small Cell Lung Cancer","Stage IIA Non-Small Cell Lung Carcinoma","Stage IIB Non-Small Cell Lung Carcinoma","Stage IIIA Non-Small Cell Lung Cancer",[465,524,525,526],"Cisplatin","Pemetrexed Disodium","Gemcitabine Hydrochloride",{"nctId":528,"briefTitle":529,"status":68,"phases":530,"primaryCompletion":531,"completion":532,"start":533,"enrollment":513,"conditions":534,"interventions":538},"NCT03472586","Ipilimumab and Nivolumab With Immunoembolization in Treating Participants With Metastatic Uveal Melanoma in the Liver",[52],"2022-12-31","2024-12-31","2018-05-02",[535,536,537],"Metastatic Malignant Neoplasm in the Liver","Metastatic Uveal Melanoma","Stage IV Uveal Melanoma AJCC v7",[480,465,539],"Embolization Therapy",{"nctId":541,"briefTitle":542,"status":68,"phases":543,"primaryCompletion":544,"completion":544,"start":545,"enrollment":546,"conditions":547,"interventions":570},"NCT03342911","Nivolumab, Carboplatin, and Paclitaxel in Treating Patients With Stage III-IV Head and Neck Squamous Cell Carcinoma That Can Be Removed by Surgery",[52],"2020-10-06","2017-11-13",34,[548,549,550,551,552,553,554,555,556,557,558,559,560,561,562,563,564,565,566,567,568,569],"Name Human Papillomavirus Positive Oropharyngeal Squamous Cell Carcinoma","Stage II Oropharyngeal Squamous Cell Carcinoma","Stage III Hypopharyngeal Squamous Cell Carcinoma","Stage III Laryngeal Squamous Cell Carcinoma","Stage III Oral Cavity Squamous Cell Carcinoma","Stage III Oropharyngeal Squamous Cell Carcinoma","Stage IV Hypopharyngeal Squamous Cell Carcinoma","Stage IV Laryngeal Squamous Cell Carcinoma","Stage IV Oral Cavity Squamous Cell Carcinoma","Stage IV Oropharyngeal Squamous Cell Carcinoma","Stage IVA Hypopharyngeal Squamous Cell Carcinoma","Stage IVA Laryngeal Squamous Cell Carcinoma","Stage IVA Oral Cavity Squamous Cell Carcinoma","Stage IVA Oropharyngeal Squamous Cell Carcinoma","Stage IVB Hypopharyngeal Squamous Cell Carcinoma","Stage IVB Laryngeal Squamous Cell Carcinoma","Stage IVB Oral Cavity Squamous Cell Carcinoma","Stage IVB Oropharyngeal Squamous Cell Carcinoma","Stage IVC Hypopharyngeal Squamous Cell Carcinoma","Stage IVC Laryngeal Squamous Cell Carcinoma","Stage IVC Oral Cavity Squamous Cell Carcinoma","Stage IVC Oropharyngeal Squamous Cell Carcinoma",[571,572,465],"Paclitaxel","Carboplatin",{"trials":574,"activeCount":62},[],{"trials":576,"activeCount":62},[],{"trials":578,"activeCount":62},[],{"intervention":572,"totalTrials":21,"cells":580},{"EARLY_PHASE1":581,"PHASE1":583,"PHASE2":596,"PHASE3":648,"PHASE4":650,"NA":652},{"trials":582,"activeCount":62},[],{"trials":584,"activeCount":62},[585],{"nctId":586,"briefTitle":587,"status":68,"phases":588,"primaryCompletion":412,"completion":589,"start":590,"enrollment":591,"conditions":592,"interventions":594},"NCT00330044","Alimta, Carboplatin and Radiation Therapy for Non Small Cell Lung Cancer",[51],"2009-10","2006-04",18,[593],"Inoperable Non Small Cell Lung Cancer",[595,572],"Premetrexed",{"trials":597,"activeCount":62},[598,612,631,635],{"nctId":599,"briefTitle":600,"status":68,"phases":601,"primaryCompletion":602,"completion":603,"start":604,"enrollment":605,"conditions":606,"interventions":607},"NCT01458366","Phase I\u002FII Study of Bendamustine in Combination With Ofatumumab, Carboplatin and Etoposide",[51,52],"2018-08-27","2020-07-23","2011-11-09",38,[27],[608,609,572,610,611],"Bendamustine","Ofatumumab","Etoposide","Stem Cell Transplant",{"nctId":613,"briefTitle":614,"status":68,"phases":615,"primaryCompletion":616,"completion":617,"start":618,"enrollment":8,"conditions":619,"interventions":628},"NCT01818063","Carboplatin and Combination Chemotherapy With or Without Veliparib in Treating Patients With Stage IIB-IIIC Breast Cancer",[52],"2015-03-01","2018-12-10","2013-04-25",[620,621,622,623,624,625,626,627],"Estrogen Receptor-negative Breast Cancer","HER2-negative Breast Cancer","Progesterone Receptor-negative Breast Cancer","Stage II Breast Cancer","Stage IIIA Breast Cancer","Stage IIIB Breast Cancer","Stage IIIC Breast Cancer","Triple-negative Breast Cancer",[571,572,629,325,630],"Doxorubicin","Veliparib",{"nctId":541,"briefTitle":542,"status":68,"phases":632,"primaryCompletion":544,"completion":544,"start":545,"enrollment":546,"conditions":633,"interventions":634},[52],[548,549,550,551,552,553,554,555,556,557,558,559,560,561,562,563,564,565,566,567,568,569],[571,572,465],{"nctId":636,"briefTitle":637,"status":68,"phases":638,"completion":639,"start":640,"conditions":641,"interventions":644},"NCT00003089","Chemotherapy, Amifostine, and Radiation Therapy in Treating Patients With Non-small Cell Lung Cancer",[52],"2004-02","1997-07",[642,643],"Drug\u002FAgent Toxicity by Tissue\u002FOrgan","Lung Cancer",[645,646,647],"amifostine trihydrate","carboplatin","paclitaxel",{"trials":649,"activeCount":62},[],{"trials":651,"activeCount":62},[],{"trials":653,"activeCount":62},[],{"intervention":480,"totalTrials":28,"cells":655},{"EARLY_PHASE1":656,"PHASE1":662,"PHASE2":694,"PHASE3":700,"PHASE4":702,"NA":704},{"trials":657,"activeCount":62},[658],{"nctId":470,"briefTitle":471,"status":68,"phases":659,"primaryCompletion":473,"completion":355,"start":474,"enrollment":475,"conditions":660,"interventions":661},[50],[477,478],[465,480],{"trials":663,"activeCount":62},[664,677],{"nctId":665,"briefTitle":666,"status":68,"phases":667,"primaryCompletion":668,"completion":669,"start":670,"enrollment":671,"conditions":672,"interventions":676},"NCT01703507","Phase I Study of Ipilimumab Combined With Whole Brain Radiation Therapy or Radiosurgery for Melanoma",[51],"2015-05-20","2018-04-11","2012-11-09",17,[673,674,675],"Recurrent Melanoma","Stage IV Melanoma","Tumors Metastatic to Brain",[480],{"nctId":678,"briefTitle":679,"status":680,"phases":681,"primaryCompletion":682,"completion":682,"start":683,"enrollment":62,"conditions":684,"interventions":692},"NCT03477864","Stereotactic Body Radiation Therapy With REGN2810 and\u002For Ipilimumab Before Surgery in Treating Participants With Progressive Advanced or Oligometastatic Prostate Cancer","WITHDRAWN",[51],"2019-11-04","2018-12-24",[685,686,687,688,689,690,691],"Stage III Prostate Cancer","Stage IIIA Prostate Cancer","Stage IIIB Prostate Cancer","Stage IIIC Prostate Cancer","Stage IV Prostate Cancer","Stage IVA Prostate Cancer","Stage IVB Prostate Cancer",[480,693],"Anti-PD-1 Monoclonal Antibody REGN2810",{"trials":695,"activeCount":62},[696],{"nctId":528,"briefTitle":529,"status":68,"phases":697,"primaryCompletion":531,"completion":532,"start":533,"enrollment":513,"conditions":698,"interventions":699},[52],[535,536,537],[480,465,539],{"trials":701,"activeCount":62},[],{"trials":703,"activeCount":62},[],{"trials":705,"activeCount":62},[],{"intervention":707,"totalTrials":28,"cells":708},"Metformin Hydrochloride",{"EARLY_PHASE1":709,"PHASE1":722,"PHASE2":724,"PHASE3":760,"PHASE4":762,"NA":764},{"trials":710,"activeCount":62},[711],{"nctId":712,"briefTitle":713,"status":68,"phases":714,"primaryCompletion":715,"completion":715,"start":716,"enrollment":8,"conditions":717,"interventions":721},"NCT03109873","Metformin Hydrochloride in Affecting Cytokines and Exosomes in Patients With Head and Neck Cancer",[50],"2020-07-31","2017-01-05",[477,718,719,720],"Lip","Oral Cavity","Pharynx",[707],{"trials":723,"activeCount":62},[],{"trials":725,"activeCount":62},[726,737,750],{"nctId":727,"briefTitle":728,"status":331,"phases":729,"primaryCompletion":730,"completion":730,"start":731,"enrollment":11,"conditions":732,"interventions":734},"NCT03076281","Metformin Hydrochloride and Doxycycline in Treating Patients With Head and Neck Squamous Cell Carcinoma",[52],"2018-12-03","2017-04-03",[477,733,719,720],"LIP",[707,735,736],"Doxycycline","Metformin +Doxycycline",{"nctId":738,"briefTitle":739,"status":331,"phases":740,"primaryCompletion":741,"completion":741,"start":742,"enrollment":743,"conditions":744,"interventions":749},"NCT02874430","Metformin Hydrochloride and Doxycycline in Treating Patients With Localized Breast or Uterine Cancer",[52],"2020-12-11","2016-06-08",29,[25,745,746,747,748],"Endometrial Clear Cell Adenocarcinoma","Endometrial Serous Adenocarcinoma","Uterine Corpus Cancer","Uterine Corpus Carcinosarcoma",[707,735],{"nctId":751,"briefTitle":752,"status":331,"phases":753,"primaryCompletion":754,"completion":755,"start":716,"enrollment":756,"conditions":757,"interventions":759},"NCT03109847","Metformin to Mitigate Sequelae of Radioactive Iodine Treatment for Thyroid Cancers",[52],"2020-12-29","2022-12-07",13,[758],"Thyroid",[707],{"trials":761,"activeCount":62},[],{"trials":763,"activeCount":62},[],{"trials":765,"activeCount":62},[],{"intervention":608,"totalTrials":767,"cells":768},3,{"EARLY_PHASE1":769,"PHASE1":771,"PHASE2":795,"PHASE3":801,"PHASE4":803,"NA":805},{"trials":770,"activeCount":62},[],{"trials":772,"activeCount":62},[773,783],{"nctId":774,"briefTitle":775,"status":680,"phases":776,"primaryCompletion":777,"completion":777,"start":778,"enrollment":62,"conditions":779,"interventions":782},"NCT02315157","Bendamustine Hydrochloride in Treating Patients With Previously Treated Multiple Myeloma",[51],"2018-11","2014-06",[780,781],"Multiple Myeloma","Plasma Cell Leukemia",[608],{"nctId":784,"briefTitle":785,"status":331,"phases":786,"primaryCompletion":787,"completion":788,"start":789,"enrollment":790,"conditions":791,"interventions":793},"NCT01352312","Combination of Pentostatin, Bendamustine and Ofatumumab for Treatment of Chronic Lymphocytic Leukemia and Lymphoma",[51],"2016-04-08","2018-05-10","2011-05-25",10,[32,792],"B-Cell Non-Hodgkin's Lymphoma",[608,794,609],"Pentostatin",{"trials":796,"activeCount":62},[797],{"nctId":599,"briefTitle":600,"status":68,"phases":798,"primaryCompletion":602,"completion":603,"start":604,"enrollment":605,"conditions":799,"interventions":800},[51,52],[27],[608,609,572,610,611],{"trials":802,"activeCount":62},[],{"trials":804,"activeCount":62},[],{"trials":806,"activeCount":62},[],{"intervention":407,"totalTrials":767,"cells":808},{"EARLY_PHASE1":809,"PHASE1":811,"PHASE2":813,"PHASE3":857,"PHASE4":859,"NA":861},{"trials":810,"activeCount":62},[],{"trials":812,"activeCount":62},[],{"trials":814,"activeCount":62},[815,819,830],{"nctId":351,"briefTitle":352,"status":68,"phases":816,"primaryCompletion":354,"completion":355,"start":356,"enrollment":357,"conditions":817,"interventions":818},[52],[359,360,361,362,363,364,365,366,367,368,369,370,371,372,373,374,375,376,377,378,379,380,381,382,383,384,30,385,386,387,388,389,390,391,392,393,394,395,396,397,398,399,400,401,402,403,404],[406,407,306,325,326,327],{"nctId":820,"briefTitle":821,"status":68,"phases":822,"primaryCompletion":823,"completion":755,"start":824,"enrollment":825,"conditions":826,"interventions":828},"NCT01349101","A Research Study of Bone Marrow Transplantation From Unrelated or Partially Matched Related Donors",[52],"2022-10-31","2011-02-10",78,[827],"Hematological Malignancies",[325,326,327,406,407,829],"Hematopoietic stem cell transplantation",{"nctId":831,"briefTitle":832,"status":68,"phases":833,"primaryCompletion":834,"completion":835,"start":836,"enrollment":837,"conditions":838,"interventions":854},"NCT01760655","Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in With High-Risk Hematologic Malignancies",[52],"2022-04-15","2022-12-05","2012-12-24",62,[839,840,841,842,368,32,843,373,844,845,846,847,848,849,850,381,30,389,851,852,853],"Acute Myeloid Leukemia With FLT3\u002FITD Mutation","Acute Myeloid Leukemia With Gene Mutations","Acute Myeloid Leukemia With Inv(3) (q21.3;q26.2); GATA2, MECOM","Acute Myeloid Leukemia With t(6;9) (p23;q34.1); DEK-NUP214","Chronic Myelogenous Leukemia, BCR-ABL1 Positive","Follicular Lymphoma","Hodgkin Lymphoma","Myelodysplastic Syndrome","Myelofibrosis","Myeloid Leukemia","Non-Hodgkin Lymphoma","Plasma Cell Myeloma","Refractory Acute Myeloid Leukemia","Secondary Acute Myeloid Leukemia","Therapy-Related Acute Myeloid Leukemia",[855,407,856,325,326,348],"Fludarabine phosphate","Therapeutic Allogeneic Lymphocytes",{"trials":858,"activeCount":62},[],{"trials":860,"activeCount":62},[],{"trials":862,"activeCount":62},[],{"intervention":571,"totalTrials":767,"cells":864},{"EARLY_PHASE1":865,"PHASE1":867,"PHASE2":869,"PHASE3":883,"PHASE4":885,"NA":887},{"trials":866,"activeCount":62},[],{"trials":868,"activeCount":62},[],{"trials":870,"activeCount":62},[871,875,879],{"nctId":613,"briefTitle":614,"status":68,"phases":872,"primaryCompletion":616,"completion":617,"start":618,"enrollment":8,"conditions":873,"interventions":874},[52],[620,621,622,623,624,625,626,627],[571,572,629,325,630],{"nctId":541,"briefTitle":542,"status":68,"phases":876,"primaryCompletion":544,"completion":544,"start":545,"enrollment":546,"conditions":877,"interventions":878},[52],[548,549,550,551,552,553,554,555,556,557,558,559,560,561,562,563,564,565,566,567,568,569],[571,572,465],{"nctId":636,"briefTitle":637,"status":68,"phases":880,"completion":639,"start":640,"conditions":881,"interventions":882},[52],[642,643],[645,646,647],{"trials":884,"activeCount":62},[],{"trials":886,"activeCount":62},[],{"trials":888,"activeCount":62},[],{"intervention":609,"totalTrials":58,"cells":890},{"EARLY_PHASE1":891,"PHASE1":893,"PHASE2":899,"PHASE3":905,"PHASE4":907,"NA":909},{"trials":892,"activeCount":62},[],{"trials":894,"activeCount":62},[895],{"nctId":784,"briefTitle":785,"status":331,"phases":896,"primaryCompletion":787,"completion":788,"start":789,"enrollment":790,"conditions":897,"interventions":898},[51],[32,792],[608,794,609],{"trials":900,"activeCount":62},[901],{"nctId":599,"briefTitle":600,"status":68,"phases":902,"primaryCompletion":602,"completion":603,"start":604,"enrollment":605,"conditions":903,"interventions":904},[51,52],[27],[608,609,572,610,611],{"trials":906,"activeCount":62},[],{"trials":908,"activeCount":62},[],{"trials":910,"activeCount":62},[],{"intervention":912,"totalTrials":58,"cells":913},"Alisertib",{"EARLY_PHASE1":914,"PHASE1":916,"PHASE2":941,"PHASE3":957,"PHASE4":959,"NA":961},{"trials":915,"activeCount":62},[],{"trials":917,"activeCount":62},[918],{"nctId":919,"briefTitle":920,"status":68,"phases":921,"primaryCompletion":922,"completion":923,"start":924,"enrollment":671,"conditions":925,"interventions":940},"NCT02186509","Alisertib and Fractionated Stereotactic Radiosurgery in Treating Patients With Recurrent High Grade Gliomas",[51],"2017-03-31","2018-12-31","2015-01-30",[926,927,928,929,930,931,932,933,934,935,936,937,938,939],"Adult Anaplastic Astrocytoma","Adult Anaplastic Ependymoma","Adult Anaplastic Oligodendroglioma","Adult Brain Stem Glioma","Adult Diffuse Astrocytoma","Adult Giant Cell Glioblastoma","Adult Glioblastoma","Adult Gliosarcoma","Adult Mixed Glioma","Adult Oligodendroglioma","Adult Pilocytic Astrocytoma","Adult Pineal Gland Astrocytoma","Adult Subependymal Giant Cell Astrocytoma","Recurrent Adult Brain Tumor",[912],{"trials":942,"activeCount":62},[943],{"nctId":944,"briefTitle":945,"status":68,"phases":946,"primaryCompletion":947,"completion":948,"start":949,"enrollment":8,"conditions":950,"interventions":954},"NCT01848067","Alisertib, Abiraterone Acetate and Prednisone in Treating Patients With Hormone-Resistant Prostate Cancer",[51,52],"2015-03-03","2016-06-23","2013-08-14",[951,952,953,689],"Adenocarcinoma of the Prostate","Hormone-resistant Prostate Cancer","Recurrent Prostate Cancer",[912,955,956],"Abiraterone acetate","Prednisone",{"trials":958,"activeCount":62},[],{"trials":960,"activeCount":62},[],{"trials":962,"activeCount":62},[],{"intervention":964,"totalTrials":58,"cells":965},"Dexamethasone",{"EARLY_PHASE1":966,"PHASE1":968,"PHASE2":982,"PHASE3":998,"PHASE4":1000,"NA":1002},{"trials":967,"activeCount":62},[],{"trials":969,"activeCount":62},[970],{"nctId":971,"briefTitle":972,"status":68,"phases":973,"primaryCompletion":974,"completion":975,"start":976,"enrollment":11,"conditions":977,"interventions":980},"NCT03472573","Palbociclib and Dexamethasone in Treating Participants With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia",[51],"2021-08-04","2022-06-09","2018-05-09",[978,979],"Recurrent B Acute Lymphoblastic Leukemia","Refractory B Acute Lymphoblastic Leukemia",[981,964],"Palbociclib",{"trials":983,"activeCount":62},[984],{"nctId":985,"briefTitle":986,"status":68,"phases":987,"primaryCompletion":988,"completion":989,"start":990,"enrollment":475,"conditions":991,"interventions":995},"NCT02224729","Bendamustine Hydrochloride, Bortezomib, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma",[52],"2016-04-21","2018-11-17","2014-08-25",[992,993,994],"Stage I Multiple Myeloma","Stage II Multiple Myeloma","Stage III Multiple Myeloma",[996,997,964],"Bendamustine hydrochloride","Bortezomib",{"trials":999,"activeCount":62},[],{"trials":1001,"activeCount":62},[],{"trials":1003,"activeCount":62},[],{"intervention":349,"totalTrials":58,"cells":1005},{"EARLY_PHASE1":1006,"PHASE1":1008,"PHASE2":1010,"PHASE3":1020,"PHASE4":1022,"NA":1024},{"trials":1007,"activeCount":62},[],{"trials":1009,"activeCount":62},[],{"trials":1011,"activeCount":62},[1012,1016],{"nctId":329,"briefTitle":330,"status":331,"phases":1013,"primaryCompletion":333,"completion":334,"start":335,"enrollment":28,"conditions":1014,"interventions":1015},[52],[323,337,338,339,340,341,32,342,343,344,345,346],[306,325,326,348,349],{"nctId":409,"briefTitle":410,"status":68,"phases":1017,"primaryCompletion":412,"completion":413,"start":414,"enrollment":415,"conditions":1018,"interventions":1019},[51,52],[417],[306,325,326,348,349],{"trials":1021,"activeCount":62},[],{"trials":1023,"activeCount":62},[],{"trials":1025,"activeCount":62},[],{"intervention":1027,"totalTrials":58,"cells":1028},"L-leucyl-L-leucine Methyl Ester",{"EARLY_PHASE1":1029,"PHASE1":1031,"PHASE2":1033,"PHASE3":1058,"PHASE4":1060,"NA":1062},{"trials":1030,"activeCount":62},[],{"trials":1032,"activeCount":62},[],{"trials":1034,"activeCount":62},[1035,1047],{"nctId":1036,"briefTitle":1037,"status":68,"phases":1038,"primaryCompletion":1039,"completion":1040,"start":1041,"enrollment":513,"conditions":1042,"interventions":1043},"NCT00429416","Research Study to Determine if an Experimental Agent, LLME Can Decrease the Incidence and Severity of Graft-Versus-Host-Disease (GVHD) Following Blood (Hematopoietic) Stem Cell Transplantation",[51,52],"2008-12","2009-05","2004-03",[417],[1027,406,1044,325,326,1045,1046],"Cytarabine","Mesna","Granulocyte Macrophage Colony-Stimulating Factor",{"nctId":1048,"briefTitle":1049,"status":331,"phases":1050,"primaryCompletion":1051,"completion":412,"start":1052,"enrollment":1053,"conditions":1054,"interventions":1056},"NCT00429039","A Study to Accelerate Immune System Recovery Following Stem Cell Transplantation",[52],"2007-10","2000-09",21,[1055],"ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION",[1057],"L-leucyl-L-leucine methyl ester",{"trials":1059,"activeCount":62},[],{"trials":1061,"activeCount":62},[],{"trials":1063,"activeCount":62},[],{"intervention":735,"totalTrials":58,"cells":1065},{"EARLY_PHASE1":1066,"PHASE1":1068,"PHASE2":1070,"PHASE3":1080,"PHASE4":1082,"NA":1084},{"trials":1067,"activeCount":62},[],{"trials":1069,"activeCount":62},[],{"trials":1071,"activeCount":62},[1072,1076],{"nctId":727,"briefTitle":728,"status":331,"phases":1073,"primaryCompletion":730,"completion":730,"start":731,"enrollment":11,"conditions":1074,"interventions":1075},[52],[477,733,719,720],[707,735,736],{"nctId":738,"briefTitle":739,"status":331,"phases":1077,"primaryCompletion":741,"completion":741,"start":742,"enrollment":743,"conditions":1078,"interventions":1079},[52],[25,745,746,747,748],[707,735],{"trials":1081,"activeCount":62},[],{"trials":1083,"activeCount":62},[],{"trials":1085,"activeCount":62},[],{"intervention":1087,"totalTrials":58,"cells":1088},"Cabazitaxel",{"EARLY_PHASE1":1089,"PHASE1":1091,"PHASE2":1105,"PHASE3":1119,"PHASE4":1121,"NA":1123},{"trials":1090,"activeCount":62},[],{"trials":1092,"activeCount":62},[1093],{"nctId":1094,"briefTitle":1095,"status":68,"phases":1096,"primaryCompletion":1097,"completion":1098,"start":1099,"enrollment":1100,"conditions":1101,"interventions":1102},"NCT01420250","Cabazitaxel With Radiation and Hormone Therapy for Prostate Cancer",[51],"2015-07-21","2020-07-21","2011-09-22",20,[15],[1087,1103,1104],"Anti-Androgen Therapy: Bicalutamide","Luteinizing Hormone-Releasing Hormone (LHRH) Agonist",{"trials":1106,"activeCount":62},[1107],{"nctId":1108,"briefTitle":1109,"status":68,"phases":1110,"primaryCompletion":1111,"completion":1112,"start":1113,"enrollment":513,"conditions":1114,"interventions":1116},"NCT01437488","Cabazitaxel in Patients With Urothelial Carcinoma Who Have Disease Progression Following Platinum-Based Chemotherapy",[52],"2014-08-04","2017-03-30","2012-02-16",[1115],"Urothelial Carcinoma",[1087,1117,1118],"Neulasta","Blood Draw",{"trials":1120,"activeCount":62},[],{"trials":1122,"activeCount":62},[],{"trials":1124,"activeCount":62},[],{"intervention":1126,"totalTrials":58,"cells":1127},"T Cell-Depleted Donor Lymphocyte",{"EARLY_PHASE1":1128,"PHASE1":1130,"PHASE2":1148,"PHASE3":1166,"PHASE4":1168,"NA":1170},{"trials":1129,"activeCount":62},[],{"trials":1131,"activeCount":62},[1132],{"nctId":1133,"briefTitle":1134,"status":680,"phases":1135,"primaryCompletion":1136,"completion":1137,"start":1138,"enrollment":62,"conditions":1139,"interventions":1147},"NCT02548468","Reduced Intensity Conditioning Before Partially Matched Donor Stem Cell Transplant in Treating Patients With Advanced Cutaneous T Cell Lymphoma",[51],"2017-01-23","2017-03-16","2015-11-20",[1140,1141,1142,1143,1144,1145,1146],"Cutaneous T-Cell Non-Hodgkin Lymphoma","Recurrent Mycosis Fungoides and Sezary Syndrome","Stage IIB Mycosis Fungoides and Sezary Syndrome","Stage IIIA Mycosis Fungoides and Sezary Syndrome","Stage IIIB Mycosis Fungoides and Sezary Syndrome","Stage IVA Mycosis Fungoides and Sezary Syndrome","Stage IVB Mycosis Fungoides and Sezary Syndrome",[406,1126,325,327,326],{"trials":1149,"activeCount":62},[1150],{"nctId":1151,"briefTitle":1152,"status":68,"phases":1153,"primaryCompletion":1154,"completion":1154,"start":1155,"enrollment":1156,"conditions":1157,"interventions":1165},"NCT02566304","Reduced Intensity Chemotherapy and Radiation Therapy Before Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies",[52],"2024-02-13","2015-11-13",35,[426,1158,368,373,845,1159,23,846,1160,850,397,1161,1162,1163,1164],"Acute Myeloid Leukemia in Remission","Indolent Non-Hodgkin Lymphoma","Myeloproliferative Neoplasm","Refractory Anemia With Excess Blasts","Refractory Anemia With Ring Sideroblasts","Refractory Cytopenia With Multilineage Dysplasia","Refractory Cytopenia With Multilineage Dysplasia and Ring Sideroblasts",[406,1126,325,326,327],{"trials":1167,"activeCount":62},[],{"trials":1169,"activeCount":62},[],{"trials":1171,"activeCount":62},[],{"intervention":1173,"totalTrials":58,"cells":1174},"Erlotinib",{"EARLY_PHASE1":1175,"PHASE1":1177,"PHASE2":1192,"PHASE3":1203,"PHASE4":1205,"NA":1207},{"trials":1176,"activeCount":62},[],{"trials":1178,"activeCount":62},[1179],{"nctId":1180,"briefTitle":1181,"status":68,"phases":1182,"primaryCompletion":413,"completion":413,"start":1183,"enrollment":756,"conditions":1184,"interventions":1189},"NCT00405405","Phase I of Biologics and Chemoradiation Therapy for Advanced Head and Neck Cancer",[51],"2006-12",[20,1185,1186,1187,1188],"Parotid Gland Cancer","Thyroid Gland Cancer","Melanoma","Stage IV Head and Neck Cancer",[524,1190,1191,1173],"Docetaxel","Bevacizumab",{"trials":1193,"activeCount":62},[1194],{"nctId":1195,"briefTitle":1196,"status":68,"phases":1197,"primaryCompletion":1198,"completion":1198,"start":1199,"enrollment":671,"conditions":1200,"interventions":1202},"NCT00983307","A Study of Erlotinib Plus Radiotherapy (RT) for Patients With Advanced or Inoperable Non-Small-Cell Lung Cancer",[52],"2012-12","2009-08-27",[1201],"Carcinoma, Non-small-cell Lung",[1173],{"trials":1204,"activeCount":62},[],{"trials":1206,"activeCount":62},[],{"trials":1208,"activeCount":62},[],{"intervention":645,"totalTrials":58,"cells":1210},{"EARLY_PHASE1":1211,"PHASE1":1213,"PHASE2":1225,"PHASE3":1231,"PHASE4":1233,"NA":1235},{"trials":1212,"activeCount":62},[],{"trials":1214,"activeCount":62},[1215],{"nctId":1216,"briefTitle":1217,"status":68,"phases":1218,"completion":1219,"start":1220,"conditions":1221,"interventions":1222},"NCT00003268","Amifostine and Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia",[51],"2003-12","1998-01",[642,337],[645,1223,1224],"cytarabine","idarubicin",{"trials":1226,"activeCount":62},[1227],{"nctId":636,"briefTitle":637,"status":68,"phases":1228,"completion":639,"start":640,"conditions":1229,"interventions":1230},[52],[642,643],[645,646,647],{"trials":1232,"activeCount":62},[],{"trials":1234,"activeCount":62},[],{"trials":1236,"activeCount":62},[],{"intervention":1238,"totalTrials":103,"cells":1239},"GM-CSF",{"EARLY_PHASE1":1240,"PHASE1":1242,"PHASE2":1244,"PHASE3":1258,"PHASE4":1260,"NA":1262},{"trials":1241,"activeCount":62},[],{"trials":1243,"activeCount":62},[],{"trials":1245,"activeCount":62},[1246],{"nctId":1247,"briefTitle":1248,"status":68,"phases":1249,"primaryCompletion":1250,"completion":1251,"start":1252,"enrollment":1253,"conditions":1254,"interventions":1257},"NCT00661622","Halt Growth of Liver Tumors From Uveal Melanoma With Closure of Liver Artery Following Injection of GM-CSF",[52],"2011-12","2012-06","2004-10",53,[1255,1256],"Uveal Melanoma","Liver Metastases",[1238],{"trials":1259,"activeCount":62},[],{"trials":1261,"activeCount":62},[],{"trials":1263,"activeCount":62},[],{"intervention":611,"totalTrials":103,"cells":1265},{"EARLY_PHASE1":1266,"PHASE1":1268,"PHASE2":1270,"PHASE3":1276,"PHASE4":1278,"NA":1280},{"trials":1267,"activeCount":62},[],{"trials":1269,"activeCount":62},[],{"trials":1271,"activeCount":62},[1272],{"nctId":599,"briefTitle":600,"status":68,"phases":1273,"primaryCompletion":602,"completion":603,"start":604,"enrollment":605,"conditions":1274,"interventions":1275},[51,52],[27],[608,609,572,610,611],{"trials":1277,"activeCount":62},[],{"trials":1279,"activeCount":62},[],{"trials":1281,"activeCount":62},[],{"intervention":1283,"totalTrials":103,"cells":1284},"CPI-613",{"EARLY_PHASE1":1285,"PHASE1":1287,"PHASE2":1289,"PHASE3":1302,"PHASE4":1304,"NA":1306},{"trials":1286,"activeCount":62},[],{"trials":1288,"activeCount":62},[],{"trials":1290,"activeCount":62},[1291],{"nctId":1292,"briefTitle":1293,"status":680,"phases":1294,"primaryCompletion":1295,"completion":1296,"start":1297,"enrollment":62,"conditions":1298,"interventions":1300},"NCT03374852","CPI-613 in Combination With Modified FOLFIRINOX in Patients With Locally Advanced Pancreatic Cancer",[52],"2019-10-05","2020-10","2018-08",[1299],"Pancreatic Ductal Adenocarcinoma",[1283,1301],"mFOLFIRNOX",{"trials":1303,"activeCount":62},[],{"trials":1305,"activeCount":62},[],{"trials":1307,"activeCount":62},[],{"intervention":1301,"totalTrials":103,"cells":1309},{"EARLY_PHASE1":1310,"PHASE1":1312,"PHASE2":1314,"PHASE3":1320,"PHASE4":1322,"NA":1324},{"trials":1311,"activeCount":62},[],{"trials":1313,"activeCount":62},[],{"trials":1315,"activeCount":62},[1316],{"nctId":1292,"briefTitle":1293,"status":680,"phases":1317,"primaryCompletion":1295,"completion":1296,"start":1297,"enrollment":62,"conditions":1318,"interventions":1319},[52],[1299],[1283,1301],{"trials":1321,"activeCount":62},[],{"trials":1323,"activeCount":62},[],{"trials":1325,"activeCount":62},[],{"intervention":1327,"totalTrials":103,"cells":1328},"Lenalidomide",{"EARLY_PHASE1":1329,"PHASE1":1331,"PHASE2":1333,"PHASE3":1346,"PHASE4":1348,"NA":1350},{"trials":1330,"activeCount":62},[],{"trials":1332,"activeCount":62},[],{"trials":1334,"activeCount":62},[1335],{"nctId":1336,"briefTitle":1337,"status":331,"phases":1338,"primaryCompletion":1339,"completion":447,"start":1340,"enrollment":450,"conditions":1341,"interventions":1345},"NCT00699842","A Dose Range Finding Study of Lenalidomide in Non-5q Chromosome Deletion in Low and Intermediate Risk Myelodysplastic Syndrome (MDS) Patients",[51,52],"2011-01","2008-07",[846,1342,1343,1344],"MDS","Low to Intermediate-1 MDS","Non-deletion 5q",[1327],{"trials":1347,"activeCount":62},[],{"trials":1349,"activeCount":62},[],{"trials":1351,"activeCount":62},[],{"intervention":1353,"totalTrials":103,"cells":1354},"Azacitidine",{"EARLY_PHASE1":1355,"PHASE1":1357,"PHASE2":1359,"PHASE3":1373,"PHASE4":1375,"NA":1377},{"trials":1356,"activeCount":62},[],{"trials":1358,"activeCount":62},[],{"trials":1360,"activeCount":62},[1361],{"nctId":1362,"briefTitle":1363,"status":68,"phases":1364,"primaryCompletion":1365,"completion":1365,"start":1366,"enrollment":1367,"conditions":1368,"interventions":1371},"NCT01869114","Sirolimus and Azacitidine in Treating Patients With High Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia That is Recurrent or Not Eligible for Intensive Chemotherapy",[52],"2024-01-03","2013-07-08",57,[361,362,363,364,365,366,1369,1370,382,30],"de Novo Myelodysplastic Syndromes","Myelodysplastic Syndrome With Isolated Del(5q)",[1372,1353],"Sirolimus",{"trials":1374,"activeCount":62},[],{"trials":1376,"activeCount":62},[],{"trials":1378,"activeCount":62},[],{"intervention":1380,"totalTrials":103,"cells":1381},"Topotecan Hydrochloride",{"EARLY_PHASE1":1382,"PHASE1":1384,"PHASE2":1386,"PHASE3":1403,"PHASE4":1405,"NA":1407},{"trials":1383,"activeCount":62},[],{"trials":1385,"activeCount":62},[],{"trials":1387,"activeCount":62},[1388],{"nctId":1389,"briefTitle":1390,"status":331,"phases":1391,"primaryCompletion":1392,"completion":1393,"start":1394,"enrollment":103,"conditions":1395,"interventions":1401},"NCT02569957","Effect of Acetylcysteine With Topotecan Hydrochloride on the Tumor Microenvironment in Patients With Persistent or Recurrent High Grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer",[52],"2016-06-10","2017-10-12","2015-10-02",[1396,1397,1398,1399,1400],"Malignant Ovarian Endometrioid Tumor","Malignant Ovarian Serous Tumor","Recurrent Fallopian Tube Carcinoma","Recurrent Ovarian Carcinoma","Recurrent Primary Peritoneal Carcinoma",[1380,1380,1402],"Acetylcysteine",{"trials":1404,"activeCount":62},[],{"trials":1406,"activeCount":62},[],{"trials":1408,"activeCount":62},[],{"intervention":1402,"totalTrials":103,"cells":1410},{"EARLY_PHASE1":1411,"PHASE1":1413,"PHASE2":1415,"PHASE3":1421,"PHASE4":1423,"NA":1425},{"trials":1412,"activeCount":62},[],{"trials":1414,"activeCount":62},[],{"trials":1416,"activeCount":62},[1417],{"nctId":1389,"briefTitle":1390,"status":331,"phases":1418,"primaryCompletion":1392,"completion":1393,"start":1394,"enrollment":103,"conditions":1419,"interventions":1420},[52],[1396,1397,1398,1399,1400],[1380,1380,1402],{"trials":1422,"activeCount":62},[],{"trials":1424,"activeCount":62},[],{"trials":1426,"activeCount":62},[],{"intervention":996,"totalTrials":103,"cells":1428},{"EARLY_PHASE1":1429,"PHASE1":1431,"PHASE2":1433,"PHASE3":1439,"PHASE4":1441,"NA":1443},{"trials":1430,"activeCount":62},[],{"trials":1432,"activeCount":62},[],{"trials":1434,"activeCount":62},[1435],{"nctId":985,"briefTitle":986,"status":68,"phases":1436,"primaryCompletion":988,"completion":989,"start":990,"enrollment":475,"conditions":1437,"interventions":1438},[52],[992,993,994],[996,997,964],{"trials":1440,"activeCount":62},[],{"trials":1442,"activeCount":62},[],{"trials":1444,"activeCount":62},[],{"intervention":1045,"totalTrials":103,"cells":1446},{"EARLY_PHASE1":1447,"PHASE1":1449,"PHASE2":1451,"PHASE3":1457,"PHASE4":1459,"NA":1461},{"trials":1448,"activeCount":62},[],{"trials":1450,"activeCount":62},[],{"trials":1452,"activeCount":62},[1453],{"nctId":1036,"briefTitle":1037,"status":68,"phases":1454,"primaryCompletion":1039,"completion":1040,"start":1041,"enrollment":513,"conditions":1455,"interventions":1456},[51,52],[417],[1027,406,1044,325,326,1045,1046],{"trials":1458,"activeCount":62},[],{"trials":1460,"activeCount":62},[],{"trials":1462,"activeCount":62},[],{"intervention":1046,"totalTrials":103,"cells":1464},{"EARLY_PHASE1":1465,"PHASE1":1467,"PHASE2":1469,"PHASE3":1475,"PHASE4":1477,"NA":1479},{"trials":1466,"activeCount":62},[],{"trials":1468,"activeCount":62},[],{"trials":1470,"activeCount":62},[1471],{"nctId":1036,"briefTitle":1037,"status":68,"phases":1472,"primaryCompletion":1039,"completion":1040,"start":1041,"enrollment":513,"conditions":1473,"interventions":1474},[51,52],[417],[1027,406,1044,325,326,1045,1046],{"trials":1476,"activeCount":62},[],{"trials":1478,"activeCount":62},[],{"trials":1480,"activeCount":62},[],{"intervention":1482,"totalTrials":103,"cells":1483},"sargramostim",{"EARLY_PHASE1":1484,"PHASE1":1486,"PHASE2":1488,"PHASE3":1499,"PHASE4":1501,"NA":1503},{"trials":1485,"activeCount":62},[],{"trials":1487,"activeCount":62},[],{"trials":1489,"activeCount":62},[1490],{"nctId":1491,"briefTitle":1492,"status":1493,"phases":1494,"start":1495,"enrollment":176,"conditions":1496,"interventions":1497},"NCT00002817","Vaccine Therapy in Treating Patients With Metastatic Melanoma","UNKNOWN",[51,52],"1996-04",[504],[1482,1498],"vaccinia-GM-CSF vaccine",{"trials":1500,"activeCount":62},[],{"trials":1502,"activeCount":62},[],{"trials":1504,"activeCount":62},[],{"intervention":1498,"totalTrials":103,"cells":1506},{"EARLY_PHASE1":1507,"PHASE1":1509,"PHASE2":1511,"PHASE3":1517,"PHASE4":1519,"NA":1521},{"trials":1508,"activeCount":62},[],{"trials":1510,"activeCount":62},[],{"trials":1512,"activeCount":62},[1513],{"nctId":1491,"briefTitle":1492,"status":1493,"phases":1514,"start":1495,"enrollment":176,"conditions":1515,"interventions":1516},[51,52],[504],[1482,1498],{"trials":1518,"activeCount":62},[],{"trials":1520,"activeCount":62},[],{"trials":1522,"activeCount":62},[],{"intervention":736,"totalTrials":103,"cells":1524},{"EARLY_PHASE1":1525,"PHASE1":1527,"PHASE2":1529,"PHASE3":1535,"PHASE4":1537,"NA":1539},{"trials":1526,"activeCount":62},[],{"trials":1528,"activeCount":62},[],{"trials":1530,"activeCount":62},[1531],{"nctId":727,"briefTitle":728,"status":331,"phases":1532,"primaryCompletion":730,"completion":730,"start":731,"enrollment":11,"conditions":1533,"interventions":1534},[52],[477,733,719,720],[707,735,736],{"trials":1536,"activeCount":62},[],{"trials":1538,"activeCount":62},[],{"trials":1540,"activeCount":62},[],{"intervention":1542,"totalTrials":103,"cells":1543},"Tbo-filgrastim",{"EARLY_PHASE1":1544,"PHASE1":1546,"PHASE2":1548,"PHASE3":1558,"PHASE4":1560,"NA":1562},{"trials":1545,"activeCount":62},[],{"trials":1547,"activeCount":62},[],{"trials":1549,"activeCount":62},[1550],{"nctId":1551,"briefTitle":1552,"status":68,"phases":1553,"primaryCompletion":1554,"completion":355,"start":1393,"enrollment":1555,"conditions":1556,"interventions":1557},"NCT03317899","Stem Cell Transplant With or Without Tbo-filgrastim in Treating Patients With Multiple Myeloma or Non-Hodgkin Lymphoma",[52],"2021-06-01",77,[27,850],[1542],{"trials":1559,"activeCount":62},[],{"trials":1561,"activeCount":62},[],{"trials":1563,"activeCount":62},[],{"intervention":1117,"totalTrials":103,"cells":1565},{"EARLY_PHASE1":1566,"PHASE1":1568,"PHASE2":1570,"PHASE3":1576,"PHASE4":1578,"NA":1580},{"trials":1567,"activeCount":62},[],{"trials":1569,"activeCount":62},[],{"trials":1571,"activeCount":62},[1572],{"nctId":1108,"briefTitle":1109,"status":68,"phases":1573,"primaryCompletion":1111,"completion":1112,"start":1113,"enrollment":513,"conditions":1574,"interventions":1575},[52],[1115],[1087,1117,1118],{"trials":1577,"activeCount":62},[],{"trials":1579,"activeCount":62},[],{"trials":1581,"activeCount":62},[],{"intervention":1118,"totalTrials":103,"cells":1583},{"EARLY_PHASE1":1584,"PHASE1":1586,"PHASE2":1588,"PHASE3":1594,"PHASE4":1596,"NA":1598},{"trials":1585,"activeCount":62},[],{"trials":1587,"activeCount":62},[],{"trials":1589,"activeCount":62},[1590],{"nctId":1108,"briefTitle":1109,"status":68,"phases":1591,"primaryCompletion":1111,"completion":1112,"start":1113,"enrollment":513,"conditions":1592,"interventions":1593},[52],[1115],[1087,1117,1118],{"trials":1595,"activeCount":62},[],{"trials":1597,"activeCount":62},[],{"trials":1599,"activeCount":62},[],{"intervention":1601,"totalTrials":103,"cells":1602},"Mechlorethamine Hydrochloride Gel",{"EARLY_PHASE1":1603,"PHASE1":1605,"PHASE2":1607,"PHASE3":1617,"PHASE4":1619,"NA":1621},{"trials":1604,"activeCount":62},[],{"trials":1606,"activeCount":62},[],{"trials":1608,"activeCount":62},[1609],{"nctId":1610,"briefTitle":1611,"status":680,"phases":1612,"primaryCompletion":1613,"completion":293,"start":1297,"enrollment":62,"conditions":1614,"interventions":1616},"NCT03288818","Low Dose Total Skin Electron Beam Radiation Therapy and Mechlorethamine Hydrochloride Gel in Treating Patients With Mycosis Fungoides",[52],"2020-12",[1615],"Mycosis Fungoides",[1601],{"trials":1618,"activeCount":62},[],{"trials":1620,"activeCount":62},[],{"trials":1622,"activeCount":62},[],{"intervention":525,"totalTrials":103,"cells":1624},{"EARLY_PHASE1":1625,"PHASE1":1627,"PHASE2":1629,"PHASE3":1635,"PHASE4":1637,"NA":1639},{"trials":1626,"activeCount":62},[],{"trials":1628,"activeCount":62},[],{"trials":1630,"activeCount":62},[1631],{"nctId":507,"briefTitle":508,"status":331,"phases":1632,"primaryCompletion":510,"completion":511,"start":512,"enrollment":513,"conditions":1633,"interventions":1634},[52],[515,516,517,518,519,520,521,522],[465,524,525,526],{"trials":1636,"activeCount":62},[],{"trials":1638,"activeCount":62},[],{"trials":1640,"activeCount":62},[],{"intervention":526,"totalTrials":103,"cells":1642},{"EARLY_PHASE1":1643,"PHASE1":1645,"PHASE2":1647,"PHASE3":1653,"PHASE4":1655,"NA":1657},{"trials":1644,"activeCount":62},[],{"trials":1646,"activeCount":62},[],{"trials":1648,"activeCount":62},[1649],{"nctId":507,"briefTitle":508,"status":331,"phases":1650,"primaryCompletion":510,"completion":511,"start":512,"enrollment":513,"conditions":1651,"interventions":1652},[52],[515,516,517,518,519,520,521,522],[465,524,525,526],{"trials":1654,"activeCount":62},[],{"trials":1656,"activeCount":62},[],{"trials":1658,"activeCount":62},[],{"intervention":1660,"totalTrials":103,"cells":1661},"Intravenous vitamin C",{"EARLY_PHASE1":1662,"PHASE1":1664,"PHASE2":1666,"PHASE3":1675,"PHASE4":1677,"NA":1679},{"trials":1663,"activeCount":62},[],{"trials":1665,"activeCount":62},[],{"trials":1667,"activeCount":62},[1668],{"nctId":1669,"briefTitle":1670,"status":331,"phases":1671,"primaryCompletion":1250,"completion":1250,"start":1672,"enrollment":58,"conditions":1673,"interventions":1674},"NCT00626444","Pilot Trial of Intravenous Vitamin C in Refractory Non-Hodgkin Lymphoma (NHL)",[52],"2008-02",[849],[1660],{"trials":1676,"activeCount":62},[],{"trials":1678,"activeCount":62},[],{"trials":1680,"activeCount":62},[],{"intervention":629,"totalTrials":103,"cells":1682},{"EARLY_PHASE1":1683,"PHASE1":1685,"PHASE2":1687,"PHASE3":1693,"PHASE4":1695,"NA":1697},{"trials":1684,"activeCount":62},[],{"trials":1686,"activeCount":62},[],{"trials":1688,"activeCount":62},[1689],{"nctId":613,"briefTitle":614,"status":68,"phases":1690,"primaryCompletion":616,"completion":617,"start":618,"enrollment":8,"conditions":1691,"interventions":1692},[52],[620,621,622,623,624,625,626,627],[571,572,629,325,630],{"trials":1694,"activeCount":62},[],{"trials":1696,"activeCount":62},[],{"trials":1698,"activeCount":62},[],{"intervention":630,"totalTrials":103,"cells":1700},{"EARLY_PHASE1":1701,"PHASE1":1703,"PHASE2":1705,"PHASE3":1711,"PHASE4":1713,"NA":1715},{"trials":1702,"activeCount":62},[],{"trials":1704,"activeCount":62},[],{"trials":1706,"activeCount":62},[1707],{"nctId":613,"briefTitle":614,"status":68,"phases":1708,"primaryCompletion":616,"completion":617,"start":618,"enrollment":8,"conditions":1709,"interventions":1710},[52],[620,621,622,623,624,625,626,627],[571,572,629,325,630],{"trials":1712,"activeCount":62},[],{"trials":1714,"activeCount":62},[],{"trials":1716,"activeCount":62},[],{"intervention":829,"totalTrials":103,"cells":1718},{"EARLY_PHASE1":1719,"PHASE1":1721,"PHASE2":1723,"PHASE3":1729,"PHASE4":1731,"NA":1733},{"trials":1720,"activeCount":62},[],{"trials":1722,"activeCount":62},[],{"trials":1724,"activeCount":62},[1725],{"nctId":820,"briefTitle":821,"status":68,"phases":1726,"primaryCompletion":823,"completion":755,"start":824,"enrollment":825,"conditions":1727,"interventions":1728},[52],[827],[325,326,327,406,407,829],{"trials":1730,"activeCount":62},[],{"trials":1732,"activeCount":62},[],{"trials":1734,"activeCount":62},[],{"intervention":1736,"totalTrials":103,"cells":1737},"Sonazoid; Perflubutane for",{"EARLY_PHASE1":1738,"PHASE1":1740,"PHASE2":1742,"PHASE3":1753,"PHASE4":1755,"NA":1757},{"trials":1739,"activeCount":62},[],{"trials":1741,"activeCount":62},[],{"trials":1743,"activeCount":62},[1744],{"nctId":1745,"briefTitle":1746,"status":68,"phases":1747,"primaryCompletion":1748,"completion":1748,"start":1749,"enrollment":1750,"conditions":1751,"interventions":1752},"NCT02652923","Contrast Ultrasound Detection of Sentinel Lymph Nodes",[51,52],"2022-01-12","2016-01-01",98,[18],[1736],{"trials":1754,"activeCount":62},[],{"trials":1756,"activeCount":62},[],{"trials":1758,"activeCount":62},[],{"intervention":1760,"totalTrials":103,"cells":1761},"Donor lymphocytes",{"EARLY_PHASE1":1762,"PHASE1":1764,"PHASE2":1766,"PHASE3":1777,"PHASE4":1779,"NA":1781},{"trials":1763,"activeCount":62},[],{"trials":1765,"activeCount":62},[],{"trials":1767,"activeCount":62},[1768],{"nctId":1769,"briefTitle":1770,"status":331,"phases":1771,"primaryCompletion":1772,"completion":1773,"start":1774,"enrollment":28,"conditions":1775,"interventions":1776},"NCT01871441","Haploidentical Donor Hematopoietic Stem Cell Transplant in Treating Patients With Hematologic Malignancies",[52],"2013-12-12","2016-10-20","2013-05-17",[23],[1760,325,326,327],{"trials":1778,"activeCount":62},[],{"trials":1780,"activeCount":62},[],{"trials":1782,"activeCount":62},[],{"intervention":1784,"totalTrials":103,"cells":1785},"Romidepsin",{"EARLY_PHASE1":1786,"PHASE1":1788,"PHASE2":1790,"PHASE3":1806,"PHASE4":1808,"NA":1810},{"trials":1787,"activeCount":62},[],{"trials":1789,"activeCount":62},[],{"trials":1791,"activeCount":62},[1792],{"nctId":1793,"briefTitle":1794,"status":331,"phases":1795,"primaryCompletion":1796,"completion":1797,"start":1798,"enrollment":8,"conditions":1799,"interventions":1804},"NCT01938833","Romidepsin and Abraxane in Treating Patients With Metastatic Inflammatory Breast Cancer",[51,52],"2016-08-18","2016-12-08","2014-04",[621,1800,1801,1802,1803],"Inflammatory Breast Cancer","Male Breast Cancer","Recurrent Breast Cancer","Stage IV Breast Cancer",[1784,1805],"Abraxane",{"trials":1807,"activeCount":62},[],{"trials":1809,"activeCount":62},[],{"trials":1811,"activeCount":62},[],{"intervention":1805,"totalTrials":103,"cells":1813},{"EARLY_PHASE1":1814,"PHASE1":1816,"PHASE2":1818,"PHASE3":1824,"PHASE4":1826,"NA":1828},{"trials":1815,"activeCount":62},[],{"trials":1817,"activeCount":62},[],{"trials":1819,"activeCount":62},[1820],{"nctId":1793,"briefTitle":1794,"status":331,"phases":1821,"primaryCompletion":1796,"completion":1797,"start":1798,"enrollment":8,"conditions":1822,"interventions":1823},[51,52],[621,1800,1801,1802,1803],[1784,1805],{"trials":1825,"activeCount":62},[],{"trials":1827,"activeCount":62},[],{"trials":1829,"activeCount":62},[],{"intervention":1831,"totalTrials":103,"cells":1832},"Interleukin-2",{"EARLY_PHASE1":1833,"PHASE1":1835,"PHASE2":1837,"PHASE3":1850,"PHASE4":1852,"NA":1854},{"trials":1834,"activeCount":62},[],{"trials":1836,"activeCount":62},[],{"trials":1838,"activeCount":62},[1839],{"nctId":1840,"briefTitle":1841,"status":68,"phases":1842,"primaryCompletion":1843,"completion":1844,"start":1845,"enrollment":16,"conditions":1846,"interventions":1848},"NCT00994643","Safety and Efficacy Study of Immunotherapy With Rituximab and Interleukin-2 in Patients With Non-Hodgkin's Lymphoma",[52],"2014-06-25","2015-06-25","2009-02-05",[1847],"High Risk Non-Hodgkin's Lymphoma",[1849,1831],"Rituximab",{"trials":1851,"activeCount":62},[],{"trials":1853,"activeCount":62},[],{"trials":1855,"activeCount":62},[],{"intervention":1857,"totalTrials":103,"cells":1858},"Enzalutamide",{"EARLY_PHASE1":1859,"PHASE1":1861,"PHASE2":1863,"PHASE3":1879,"PHASE4":1881,"NA":1883},{"trials":1860,"activeCount":62},[],{"trials":1862,"activeCount":62},[],{"trials":1864,"activeCount":62},[1865],{"nctId":1866,"briefTitle":1867,"status":331,"phases":1868,"primaryCompletion":755,"completion":1869,"start":1870,"enrollment":1871,"conditions":1872,"interventions":1877},"NCT02555189","Enzalutamide With Ribociclib in Treating Patients With Metastatic Castrate-Resistant, Chemotherapy Naive Prostate Cancer That Retains Retinoblastoma Expression",[51,52],"2023-09-01","2015-12-01",52,[1873,1874,1875,1876],"Castration-Resistant Prostate Carcinoma","Metastatic Prostate Carcinoma","Prostate Carcinoma Metastatic in the Bone","Stage IV Prostate Cancer AJCC v7",[1857,1878],"Ribociclib",{"trials":1880,"activeCount":62},[],{"trials":1882,"activeCount":62},[],{"trials":1884,"activeCount":62},[],{"intervention":1878,"totalTrials":103,"cells":1886},{"EARLY_PHASE1":1887,"PHASE1":1889,"PHASE2":1891,"PHASE3":1897,"PHASE4":1899,"NA":1901},{"trials":1888,"activeCount":62},[],{"trials":1890,"activeCount":62},[],{"trials":1892,"activeCount":62},[1893],{"nctId":1866,"briefTitle":1867,"status":331,"phases":1894,"primaryCompletion":755,"completion":1869,"start":1870,"enrollment":1871,"conditions":1895,"interventions":1896},[51,52],[1873,1874,1875,1876],[1857,1878],{"trials":1898,"activeCount":62},[],{"trials":1900,"activeCount":62},[],{"trials":1902,"activeCount":62},[],{"intervention":539,"totalTrials":103,"cells":1904},{"EARLY_PHASE1":1905,"PHASE1":1907,"PHASE2":1909,"PHASE3":1915,"PHASE4":1917,"NA":1919},{"trials":1906,"activeCount":62},[],{"trials":1908,"activeCount":62},[],{"trials":1910,"activeCount":62},[1911],{"nctId":528,"briefTitle":529,"status":68,"phases":1912,"primaryCompletion":531,"completion":532,"start":533,"enrollment":513,"conditions":1913,"interventions":1914},[52],[535,536,537],[480,465,539],{"trials":1916,"activeCount":62},[],{"trials":1918,"activeCount":62},[],{"trials":1920,"activeCount":62},[],{"intervention":1922,"totalTrials":103,"cells":1923},"Bortezomib with mitoxantrone, etoposide and cytarabine",{"EARLY_PHASE1":1924,"PHASE1":1926,"PHASE2":1928,"PHASE3":1942,"PHASE4":1944,"NA":1946},{"trials":1925,"activeCount":62},[],{"trials":1927,"activeCount":62},[],{"trials":1929,"activeCount":62},[1930],{"nctId":1931,"briefTitle":1932,"status":68,"phases":1933,"primaryCompletion":334,"completion":1934,"start":414,"enrollment":1935,"conditions":1936,"interventions":1939},"NCT00410423","Study of VELCADE® With Mitoxantrone and Etoposide for Leukemias",[51,52],"2014-09",55,[1937,1938],"Relapsed Acute Leukemia","Refractory Acute Leukemia",[1922,1940,1941],"Bortezomib 1.0mg\u002Fm^2","Bortezomib 1.3mg\u002Fm^2",{"trials":1943,"activeCount":62},[],{"trials":1945,"activeCount":62},[],{"trials":1947,"activeCount":62},[],{"intervention":1940,"totalTrials":103,"cells":1949},{"EARLY_PHASE1":1950,"PHASE1":1952,"PHASE2":1954,"PHASE3":1960,"PHASE4":1962,"NA":1964},{"trials":1951,"activeCount":62},[],{"trials":1953,"activeCount":62},[],{"trials":1955,"activeCount":62},[1956],{"nctId":1931,"briefTitle":1932,"status":68,"phases":1957,"primaryCompletion":334,"completion":1934,"start":414,"enrollment":1935,"conditions":1958,"interventions":1959},[51,52],[1937,1938],[1922,1940,1941],{"trials":1961,"activeCount":62},[],{"trials":1963,"activeCount":62},[],{"trials":1965,"activeCount":62},[],{"intervention":1941,"totalTrials":103,"cells":1967},{"EARLY_PHASE1":1968,"PHASE1":1970,"PHASE2":1972,"PHASE3":1978,"PHASE4":1980,"NA":1982},{"trials":1969,"activeCount":62},[],{"trials":1971,"activeCount":62},[],{"trials":1973,"activeCount":62},[1974],{"nctId":1931,"briefTitle":1932,"status":68,"phases":1975,"primaryCompletion":334,"completion":1934,"start":414,"enrollment":1935,"conditions":1976,"interventions":1977},[51,52],[1937,1938],[1922,1940,1941],{"trials":1979,"activeCount":62},[],{"trials":1981,"activeCount":62},[],{"trials":1983,"activeCount":62},[],{"intervention":1985,"totalTrials":103,"cells":1986},"Ziv-Aflibercept",{"EARLY_PHASE1":1987,"PHASE1":1989,"PHASE2":1991,"PHASE3":2002,"PHASE4":2004,"NA":2006},{"trials":1988,"activeCount":62},[],{"trials":1990,"activeCount":62},[],{"trials":1992,"activeCount":62},[1993],{"nctId":1994,"briefTitle":1995,"status":331,"phases":1996,"primaryCompletion":1997,"completion":1998,"start":1999,"enrollment":767,"conditions":2000,"interventions":2001},"NCT03712904","Stereotactic Body Radiation Therapy and Aflibercept in Treating Patients With Uveal Melanoma",[52],"2022-09-20","2022-12-23","2019-08-09",[1255],[1985],{"trials":2003,"activeCount":62},[],{"trials":2005,"activeCount":62},[],{"trials":2007,"activeCount":62},[],{"intervention":2009,"totalTrials":103,"cells":2010},"Pasireotide",{"EARLY_PHASE1":2011,"PHASE1":2013,"PHASE2":2015,"PHASE3":2029,"PHASE4":2031,"NA":2033},{"trials":2012,"activeCount":62},[],{"trials":2014,"activeCount":62},[],{"trials":2016,"activeCount":62},[2017],{"nctId":2018,"briefTitle":2019,"status":331,"phases":2020,"primaryCompletion":2021,"completion":2022,"start":2023,"enrollment":9,"conditions":2024,"interventions":2027},"NCT01313559","Pasireotide (SOM230) With or Without Everolimus in Treating Patients With Hormone Resistant, Chemotherapy Naive Prostate Cancer",[52],"2012-09-15","2012-11-29","2011-06",[2025,2026,15],"Castrate Resistant Prostate Cancer","Chemotherapy Naive Prostate Cancer",[2009,2028],"Everolimus",{"trials":2030,"activeCount":62},[],{"trials":2032,"activeCount":62},[],{"trials":2034,"activeCount":62},[],{"intervention":2028,"totalTrials":103,"cells":2036},{"EARLY_PHASE1":2037,"PHASE1":2039,"PHASE2":2041,"PHASE3":2047,"PHASE4":2049,"NA":2051},{"trials":2038,"activeCount":62},[],{"trials":2040,"activeCount":62},[],{"trials":2042,"activeCount":62},[2043],{"nctId":2018,"briefTitle":2019,"status":331,"phases":2044,"primaryCompletion":2021,"completion":2022,"start":2023,"enrollment":9,"conditions":2045,"interventions":2046},[52],[2025,2026,15],[2009,2028],{"trials":2048,"activeCount":62},[],{"trials":2050,"activeCount":62},[],{"trials":2052,"activeCount":62},[],{"intervention":955,"totalTrials":103,"cells":2054},{"EARLY_PHASE1":2055,"PHASE1":2057,"PHASE2":2059,"PHASE3":2065,"PHASE4":2067,"NA":2069},{"trials":2056,"activeCount":62},[],{"trials":2058,"activeCount":62},[],{"trials":2060,"activeCount":62},[2061],{"nctId":944,"briefTitle":945,"status":68,"phases":2062,"primaryCompletion":947,"completion":948,"start":949,"enrollment":8,"conditions":2063,"interventions":2064},[51,52],[951,952,953,689],[912,955,956],{"trials":2066,"activeCount":62},[],{"trials":2068,"activeCount":62},[],{"trials":2070,"activeCount":62},[],{"intervention":956,"totalTrials":103,"cells":2072},{"EARLY_PHASE1":2073,"PHASE1":2075,"PHASE2":2077,"PHASE3":2083,"PHASE4":2085,"NA":2087},{"trials":2074,"activeCount":62},[],{"trials":2076,"activeCount":62},[],{"trials":2078,"activeCount":62},[2079],{"nctId":944,"briefTitle":945,"status":68,"phases":2080,"primaryCompletion":947,"completion":948,"start":949,"enrollment":8,"conditions":2081,"interventions":2082},[51,52],[951,952,953,689],[912,955,956],{"trials":2084,"activeCount":62},[],{"trials":2086,"activeCount":62},[],{"trials":2088,"activeCount":62},[],{"intervention":855,"totalTrials":103,"cells":2090},{"EARLY_PHASE1":2091,"PHASE1":2093,"PHASE2":2095,"PHASE3":2101,"PHASE4":2103,"NA":2105},{"trials":2092,"activeCount":62},[],{"trials":2094,"activeCount":62},[],{"trials":2096,"activeCount":62},[2097],{"nctId":831,"briefTitle":832,"status":68,"phases":2098,"primaryCompletion":834,"completion":835,"start":836,"enrollment":837,"conditions":2099,"interventions":2100},[52],[839,840,841,842,368,32,843,373,844,845,846,847,848,849,850,381,30,389,851,852,853],[855,407,856,325,326,348],{"trials":2102,"activeCount":62},[],{"trials":2104,"activeCount":62},[],{"trials":2106,"activeCount":62},[],{"intervention":856,"totalTrials":103,"cells":2108},{"EARLY_PHASE1":2109,"PHASE1":2111,"PHASE2":2113,"PHASE3":2119,"PHASE4":2121,"NA":2123},{"trials":2110,"activeCount":62},[],{"trials":2112,"activeCount":62},[],{"trials":2114,"activeCount":62},[2115],{"nctId":831,"briefTitle":832,"status":68,"phases":2116,"primaryCompletion":834,"completion":835,"start":836,"enrollment":837,"conditions":2117,"interventions":2118},[52],[839,840,841,842,368,32,843,373,844,845,846,847,848,849,850,381,30,389,851,852,853],[855,407,856,325,326,348],{"trials":2120,"activeCount":62},[],{"trials":2122,"activeCount":62},[],{"trials":2124,"activeCount":62},[],{"intervention":456,"totalTrials":103,"cells":2126},{"EARLY_PHASE1":2127,"PHASE1":2129,"PHASE2":2131,"PHASE3":2137,"PHASE4":2139,"NA":2141},{"trials":2128,"activeCount":62},[],{"trials":2130,"activeCount":62},[],{"trials":2132,"activeCount":62},[2133],{"nctId":444,"briefTitle":445,"status":331,"phases":2134,"primaryCompletion":447,"completion":448,"start":449,"enrollment":450,"conditions":2135,"interventions":2136},[51,52],[417,452,453,344,27,346,454],[406,456,306,457],{"trials":2138,"activeCount":62},[],{"trials":2140,"activeCount":62},[],{"trials":2142,"activeCount":62},[],{"intervention":457,"totalTrials":103,"cells":2144},{"EARLY_PHASE1":2145,"PHASE1":2147,"PHASE2":2149,"PHASE3":2155,"PHASE4":2157,"NA":2159},{"trials":2146,"activeCount":62},[],{"trials":2148,"activeCount":62},[],{"trials":2150,"activeCount":62},[2151],{"nctId":444,"briefTitle":445,"status":331,"phases":2152,"primaryCompletion":447,"completion":448,"start":449,"enrollment":450,"conditions":2153,"interventions":2154},[51,52],[417,452,453,344,27,346,454],[406,456,306,457],{"trials":2156,"activeCount":62},[],{"trials":2158,"activeCount":62},[],{"trials":2160,"activeCount":62},[],{"intervention":2162,"totalTrials":103,"cells":2163},"Digoxin",{"EARLY_PHASE1":2164,"PHASE1":2166,"PHASE2":2168,"PHASE3":2179,"PHASE4":2181,"NA":2183},{"trials":2165,"activeCount":62},[],{"trials":2167,"activeCount":62},[],{"trials":2169,"activeCount":62},[2170],{"nctId":2171,"briefTitle":2172,"status":68,"phases":2173,"primaryCompletion":2174,"completion":334,"start":2175,"enrollment":2176,"conditions":2177,"interventions":2178},"NCT01162135","Digoxin for Recurrent Prostate Cancer",[52],"2013-03","2010-09",16,[15],[2162],{"trials":2180,"activeCount":62},[],{"trials":2182,"activeCount":62},[],{"trials":2184,"activeCount":62},[],{"intervention":2186,"totalTrials":103,"cells":2187},"PD-0332991",{"EARLY_PHASE1":2188,"PHASE1":2190,"PHASE2":2192,"PHASE3":2206,"PHASE4":2208,"NA":2210},{"trials":2189,"activeCount":62},[],{"trials":2191,"activeCount":62},[],{"trials":2193,"activeCount":62},[2194],{"nctId":2195,"briefTitle":2196,"status":68,"phases":2197,"primaryCompletion":2198,"completion":2199,"start":789,"enrollment":2200,"conditions":2201,"interventions":2205},"NCT01356628","A Clinical Research Study to Determine Whether PD 0332991 May Be Effective in Treating Patients With Liver Cancer",[52],"2023-06-01","2023-12-16",23,[2202,2203,2204],"Advanced Hepatocellular Carcinoma","HCC","Liver Cancer",[2186],{"trials":2207,"activeCount":62},[],{"trials":2209,"activeCount":62},[],{"trials":2211,"activeCount":62},[],{"intervention":2213,"totalTrials":103,"cells":2214},"Ixabepilone",{"EARLY_PHASE1":2215,"PHASE1":2217,"PHASE2":2219,"PHASE3":2233,"PHASE4":2235,"NA":2237},{"trials":2216,"activeCount":62},[],{"trials":2218,"activeCount":62},[],{"trials":2220,"activeCount":62},[2221],{"nctId":2222,"briefTitle":2223,"status":680,"phases":2224,"primaryCompletion":2225,"completion":2226,"start":2227,"enrollment":62,"conditions":2228,"interventions":2230},"NCT01349088","Investigational Drug in Combination With Two Chemotherapy Drugs in Women With Locally Recurrent or Metastatic Breast Cancer",[51,52],"2015-09","2018-09","2013-12",[18,2229,1803],"Metastatic Breast Cancer",[2213,2231,2232],"Capecitabine","Motesanib",{"trials":2234,"activeCount":62},[],{"trials":2236,"activeCount":62},[],{"trials":2238,"activeCount":62},[],{"intervention":2231,"totalTrials":103,"cells":2240},{"EARLY_PHASE1":2241,"PHASE1":2243,"PHASE2":2245,"PHASE3":2251,"PHASE4":2253,"NA":2255},{"trials":2242,"activeCount":62},[],{"trials":2244,"activeCount":62},[],{"trials":2246,"activeCount":62},[2247],{"nctId":2222,"briefTitle":2223,"status":680,"phases":2248,"primaryCompletion":2225,"completion":2226,"start":2227,"enrollment":62,"conditions":2249,"interventions":2250},[51,52],[18,2229,1803],[2213,2231,2232],{"trials":2252,"activeCount":62},[],{"trials":2254,"activeCount":62},[],{"trials":2256,"activeCount":62},[],{"intervention":2232,"totalTrials":103,"cells":2258},{"EARLY_PHASE1":2259,"PHASE1":2261,"PHASE2":2263,"PHASE3":2269,"PHASE4":2271,"NA":2273},{"trials":2260,"activeCount":62},[],{"trials":2262,"activeCount":62},[],{"trials":2264,"activeCount":62},[2265],{"nctId":2222,"briefTitle":2223,"status":680,"phases":2266,"primaryCompletion":2225,"completion":2226,"start":2227,"enrollment":62,"conditions":2267,"interventions":2268},[51,52],[18,2229,1803],[2213,2231,2232],{"trials":2270,"activeCount":62},[],{"trials":2272,"activeCount":62},[],{"trials":2274,"activeCount":62},[],{"intervention":2276,"totalTrials":58,"cells":2277},"Perflutren Lipid Microspheres",{"EARLY_PHASE1":2278,"PHASE1":2290,"PHASE2":2301,"PHASE3":2303,"PHASE4":2305,"NA":2307},{"trials":2279,"activeCount":62},[2280],{"nctId":2281,"briefTitle":2282,"status":68,"phases":2283,"primaryCompletion":2284,"completion":2284,"start":2285,"enrollment":2286,"conditions":2287,"interventions":2289},"NCT03297112","Contrast-Enhanced Subharmonic Ultrasound Imaging in Improving Characterization of Adnexal Masses in Patients Undergoing Surgery",[50],"2018-09-04","2017-08-01",12,[2288],"Adnexal Mass",[2276],{"trials":2291,"activeCount":62},[2292],{"nctId":2293,"briefTitle":2294,"status":68,"phases":2295,"primaryCompletion":2296,"completion":2296,"start":2297,"enrollment":2298,"conditions":2299,"interventions":2300},"NCT03045497","Contrast-Enhanced Ultrasound in Predicting Treatment Response in Patients With Liver Cancer Receiving Transarterial Chemoembolization With Drug Eluting Beads",[51],"2013-12-05","2012-12-12",15,[298],[2276],{"trials":2302,"activeCount":62},[],{"trials":2304,"activeCount":62},[],{"trials":2306,"activeCount":62},[],{"trials":2308,"activeCount":62},[],{"intervention":2310,"totalTrials":58,"cells":2311},"Temozolomide",{"EARLY_PHASE1":2312,"PHASE1":2324,"PHASE2":2336,"PHASE3":2338,"PHASE4":2340,"NA":2342},{"trials":2313,"activeCount":62},[2314],{"nctId":2315,"briefTitle":2316,"status":68,"phases":2317,"primaryCompletion":2318,"completion":2319,"start":2320,"enrollment":176,"conditions":2321,"interventions":2323},"NCT03477110","Temozolomide, Radiation Therapy, and Tumor Treating Fields Therapy in Treating Participants With Glioblastoma",[50],"2021-04-21","2024-01-26","2018-05-04",[2322],"Glioblastoma",[2310],{"trials":2325,"activeCount":62},[2326],{"nctId":2327,"briefTitle":2328,"status":68,"phases":2329,"primaryCompletion":269,"completion":269,"start":2330,"enrollment":1156,"conditions":2331,"interventions":2334},"NCT00639262","Combination of Sorafenib and Radiation for Brain Metastases and Primary Brain Tumors",[51],"2008-03",[2332,2333],"Brain Metastases","Primary Brain Tumors",[2335,2310],"Sorafenib",{"trials":2337,"activeCount":62},[],{"trials":2339,"activeCount":62},[],{"trials":2341,"activeCount":62},[],{"trials":2343,"activeCount":62},[],{"intervention":1224,"totalTrials":58,"cells":2345},{"EARLY_PHASE1":2346,"PHASE1":2366,"PHASE2":2372,"PHASE3":2374,"PHASE4":2376,"NA":2378},{"trials":2347,"activeCount":62},[2348],{"nctId":2349,"briefTitle":2350,"status":68,"phases":2351,"primaryCompletion":2352,"completion":2352,"start":2353,"enrollment":1935,"conditions":2354,"interventions":2364},"NCT01822015","Sirolimus, Idarubicin, and Cytarabine in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia",[50],"2019-12-12","2013-03-15",[2355,2356,2357,2358,2359,361,362,363,365,366,2360,2361,2362,2363],"Adult Acute Megakaryoblastic Leukemia (M7)","Adult Acute Monoblastic Leukemia (M5a)","Adult Acute Monocytic Leukemia (M5b)","Adult Acute Myeloblastic Leukemia With Maturation (M2)","Adult Acute Myeloblastic Leukemia Without Maturation (M1)","Adult Acute Myelomonocytic Leukemia (M4)","Adult Erythroleukemia (M6a)","Adult Pure Erythroid Leukemia (M6b)","Untreated Adult Acute Myeloid Leukemia",[1372,2365,1044],"Idarubicin",{"trials":2367,"activeCount":62},[2368],{"nctId":1216,"briefTitle":1217,"status":68,"phases":2369,"completion":1219,"start":1220,"conditions":2370,"interventions":2371},[51],[642,337],[645,1223,1224],{"trials":2373,"activeCount":62},[],{"trials":2375,"activeCount":62},[],{"trials":2377,"activeCount":62},[],{"trials":2379,"activeCount":62},[],{"intervention":595,"totalTrials":103,"cells":2381},{"EARLY_PHASE1":2382,"PHASE1":2384,"PHASE2":2390,"PHASE3":2392,"PHASE4":2394,"NA":2396},{"trials":2383,"activeCount":62},[],{"trials":2385,"activeCount":62},[2386],{"nctId":586,"briefTitle":587,"status":68,"phases":2387,"primaryCompletion":412,"completion":589,"start":590,"enrollment":591,"conditions":2388,"interventions":2389},[51],[593],[595,572],{"trials":2391,"activeCount":62},[],{"trials":2393,"activeCount":62},[],{"trials":2395,"activeCount":62},[],{"trials":2397,"activeCount":62},[],{"intervention":981,"totalTrials":103,"cells":2399},{"EARLY_PHASE1":2400,"PHASE1":2402,"PHASE2":2408,"PHASE3":2410,"PHASE4":2412,"NA":2414},{"trials":2401,"activeCount":62},[],{"trials":2403,"activeCount":62},[2404],{"nctId":971,"briefTitle":972,"status":68,"phases":2405,"primaryCompletion":974,"completion":975,"start":976,"enrollment":11,"conditions":2406,"interventions":2407},[51],[978,979],[981,964],{"trials":2409,"activeCount":62},[],{"trials":2411,"activeCount":62},[],{"trials":2413,"activeCount":62},[],{"trials":2415,"activeCount":62},[],{"intervention":2417,"totalTrials":103,"cells":2418},"Vorinostat",{"EARLY_PHASE1":2419,"PHASE1":2421,"PHASE2":2432,"PHASE3":2434,"PHASE4":2436,"NA":2438},{"trials":2420,"activeCount":62},[],{"trials":2422,"activeCount":62},[2423],{"nctId":2424,"briefTitle":2425,"status":68,"phases":2426,"primaryCompletion":2427,"completion":2428,"start":2429,"enrollment":671,"conditions":2430,"interventions":2431},"NCT00838929","Study of the Combination of Vorinostat and Radiation Therapy for the Treatment of Patients With Brain Metastases",[51],"2012-01","2015-03","2009-03",[2332],[2417],{"trials":2433,"activeCount":62},[],{"trials":2435,"activeCount":62},[],{"trials":2437,"activeCount":62},[],{"trials":2439,"activeCount":62},[],{"intervention":2441,"totalTrials":103,"cells":2442},"Niraparib",{"EARLY_PHASE1":2443,"PHASE1":2445,"PHASE2":2459,"PHASE3":2461,"PHASE4":2463,"NA":2465},{"trials":2444,"activeCount":62},[],{"trials":2446,"activeCount":62},[2447],{"nctId":2448,"briefTitle":2449,"status":68,"phases":2450,"primaryCompletion":2451,"completion":2452,"start":2453,"enrollment":513,"conditions":2454,"interventions":2458},"NCT03076203","Phase IB Trial of Radium-223 and Niraparib in Patients With Castrate Resistant Prostate Cancer (NiraRad)",[51],"2020-01-13","2022-11-07","2017-09-22",[2455,2456,2457],"Prostate Carcinoma Metastatic to the Bone","Stage IV Prostate Adenocarcinoma","Hormone-refractory Prostate Cancer",[2441],{"trials":2460,"activeCount":62},[],{"trials":2462,"activeCount":62},[],{"trials":2464,"activeCount":62},[],{"trials":2466,"activeCount":62},[],{"intervention":2335,"totalTrials":103,"cells":2468},{"EARLY_PHASE1":2469,"PHASE1":2471,"PHASE2":2477,"PHASE3":2479,"PHASE4":2481,"NA":2483},{"trials":2470,"activeCount":62},[],{"trials":2472,"activeCount":62},[2473],{"nctId":2327,"briefTitle":2328,"status":68,"phases":2474,"primaryCompletion":269,"completion":269,"start":2330,"enrollment":1156,"conditions":2475,"interventions":2476},[51],[2332,2333],[2335,2310],{"trials":2478,"activeCount":62},[],{"trials":2480,"activeCount":62},[],{"trials":2482,"activeCount":62},[],{"trials":2484,"activeCount":62},[],{"intervention":2486,"totalTrials":103,"cells":2487},"Ad5-hGCC-PADRE vaccine",{"EARLY_PHASE1":2488,"PHASE1":2490,"PHASE2":2502,"PHASE3":2504,"PHASE4":2506,"NA":2508},{"trials":2489,"activeCount":62},[],{"trials":2491,"activeCount":62},[2492],{"nctId":2493,"briefTitle":2494,"status":68,"phases":2495,"primaryCompletion":2496,"completion":2497,"start":2498,"enrollment":790,"conditions":2499,"interventions":2501},"NCT01972737","Phase I Study of Ad5-hGCC (Human Guanylyl Cyclase C)-PADRE in Stage I\u002FII Colon Cancer",[51],"2014-06-03","2016-01-13","2013-10",[2500],"Colon Cancer",[2486],{"trials":2503,"activeCount":62},[],{"trials":2505,"activeCount":62},[],{"trials":2507,"activeCount":62},[],{"trials":2509,"activeCount":62},[],{"intervention":1103,"totalTrials":103,"cells":2511},{"EARLY_PHASE1":2512,"PHASE1":2514,"PHASE2":2520,"PHASE3":2522,"PHASE4":2524,"NA":2526},{"trials":2513,"activeCount":62},[],{"trials":2515,"activeCount":62},[2516],{"nctId":1094,"briefTitle":1095,"status":68,"phases":2517,"primaryCompletion":1097,"completion":1098,"start":1099,"enrollment":1100,"conditions":2518,"interventions":2519},[51],[15],[1087,1103,1104],{"trials":2521,"activeCount":62},[],{"trials":2523,"activeCount":62},[],{"trials":2525,"activeCount":62},[],{"trials":2527,"activeCount":62},[],{"intervention":1104,"totalTrials":103,"cells":2529},{"EARLY_PHASE1":2530,"PHASE1":2532,"PHASE2":2538,"PHASE3":2540,"PHASE4":2542,"NA":2544},{"trials":2531,"activeCount":62},[],{"trials":2533,"activeCount":62},[2534],{"nctId":1094,"briefTitle":1095,"status":68,"phases":2535,"primaryCompletion":1097,"completion":1098,"start":1099,"enrollment":1100,"conditions":2536,"interventions":2537},[51],[15],[1087,1103,1104],{"trials":2539,"activeCount":62},[],{"trials":2541,"activeCount":62},[],{"trials":2543,"activeCount":62},[],{"trials":2545,"activeCount":62},[],{"intervention":2547,"totalTrials":103,"cells":2548},"Gemcitabine and Erlotinib",{"EARLY_PHASE1":2549,"PHASE1":2551,"PHASE2":2561,"PHASE3":2563,"PHASE4":2565,"NA":2567},{"trials":2550,"activeCount":62},[],{"trials":2552,"activeCount":62},[2553],{"nctId":2554,"briefTitle":2555,"status":68,"phases":2556,"primaryCompletion":1250,"completion":1250,"start":2557,"enrollment":513,"conditions":2558,"interventions":2560},"NCT00954525","Intravenous Vitamin C in Combination With Standard Chemotherapy for Pancreatic Cancer",[51],"2009-07",[2559],"Metastatic Pancreatic Cancer",[2547],{"trials":2562,"activeCount":62},[],{"trials":2564,"activeCount":62},[],{"trials":2566,"activeCount":62},[],{"trials":2568,"activeCount":62},[],{"intervention":2570,"totalTrials":103,"cells":2571},"ZD1839",{"EARLY_PHASE1":2572,"PHASE1":2574,"PHASE2":2584,"PHASE3":2586,"PHASE4":2588,"NA":2590},{"trials":2573,"activeCount":62},[],{"trials":2575,"activeCount":62},[2576],{"nctId":2577,"briefTitle":2578,"status":68,"phases":2579,"primaryCompletion":2580,"completion":2175,"start":1219,"enrollment":756,"conditions":2581,"interventions":2583},"NCT00328562","ZD1839 With Hypofractionated Radiation Therapy With an Immobilization Device for Advanced Non-Small Cell Lung Cancer",[51],"2008-04",[2582],"Non-Small Cell Lung Carcinoma (NSCLC)",[2570],{"trials":2585,"activeCount":62},[],{"trials":2587,"activeCount":62},[],{"trials":2589,"activeCount":62},[],{"trials":2591,"activeCount":62},[],{"intervention":2593,"totalTrials":103,"cells":2594},"IGF-1R\u002FAS ODN",{"EARLY_PHASE1":2595,"PHASE1":2597,"PHASE2":2608,"PHASE3":2610,"PHASE4":2612,"NA":2614},{"trials":2596,"activeCount":62},[],{"trials":2598,"activeCount":62},[2599],{"nctId":2600,"briefTitle":2601,"status":68,"phases":2602,"primaryCompletion":2603,"completion":2603,"start":2604,"enrollment":756,"conditions":2605,"interventions":2607},"NCT01550523","Pilot Immunotherapy Trial for Recurrent Malignant Gliomas",[51],"2013-06-25","2012-02-09",[2606],"Malignant Glioma of Brain",[2593],{"trials":2609,"activeCount":62},[],{"trials":2611,"activeCount":62},[],{"trials":2613,"activeCount":62},[],{"trials":2615,"activeCount":62},[],{"intervention":2617,"totalTrials":103,"cells":2618},"EPO906",{"EARLY_PHASE1":2619,"PHASE1":2621,"PHASE2":2632,"PHASE3":2634,"PHASE4":2636,"NA":2638},{"trials":2620,"activeCount":62},[],{"trials":2622,"activeCount":62},[2623],{"nctId":2624,"briefTitle":2625,"status":68,"phases":2626,"primaryCompletion":2627,"completion":2557,"start":639,"enrollment":72,"conditions":2628,"interventions":2631},"NCT00328458","EPO906 Plus Radiation Therapy for the Treatment of Cancer Patients",[51],"2008-05",[2629,2630],"Central Nervous System Neoplasms","Head and Neck Neoplasms",[2617],{"trials":2633,"activeCount":62},[],{"trials":2635,"activeCount":62},[],{"trials":2637,"activeCount":62},[],{"trials":2639,"activeCount":62},[],{"intervention":2641,"totalTrials":103,"cells":2642},"STAT Inhibitor OPB-111077",{"EARLY_PHASE1":2643,"PHASE1":2645,"PHASE2":2660,"PHASE3":2662,"PHASE4":2664,"NA":2666},{"trials":2644,"activeCount":62},[],{"trials":2646,"activeCount":62},[2647],{"nctId":2648,"briefTitle":2649,"status":68,"phases":2650,"primaryCompletion":2651,"completion":2652,"start":2653,"enrollment":2654,"conditions":2655,"interventions":2657},"NCT03063944","STAT Inhibitor OPB-111077, Decitabine and Venetoclax in Treating Patients With Acute Myeloid Leukemia That Is Refractory, Relapsed or Newly Diagnosed and Ineligible for Intensive Chemotherapy",[51],"2024-01-18","2024-03-04","2017-03-17",37,[426,2656,851],"Recurrent Acute Myeloid Leukemia",[2641,2658,2659],"Decitabine","Venetoclax",{"trials":2661,"activeCount":62},[],{"trials":2663,"activeCount":62},[],{"trials":2665,"activeCount":62},[],{"trials":2667,"activeCount":62},[],{"intervention":2658,"totalTrials":103,"cells":2669},{"EARLY_PHASE1":2670,"PHASE1":2672,"PHASE2":2678,"PHASE3":2680,"PHASE4":2682,"NA":2684},{"trials":2671,"activeCount":62},[],{"trials":2673,"activeCount":62},[2674],{"nctId":2648,"briefTitle":2649,"status":68,"phases":2675,"primaryCompletion":2651,"completion":2652,"start":2653,"enrollment":2654,"conditions":2676,"interventions":2677},[51],[426,2656,851],[2641,2658,2659],{"trials":2679,"activeCount":62},[],{"trials":2681,"activeCount":62},[],{"trials":2683,"activeCount":62},[],{"trials":2685,"activeCount":62},[],{"intervention":2659,"totalTrials":103,"cells":2687},{"EARLY_PHASE1":2688,"PHASE1":2690,"PHASE2":2696,"PHASE3":2698,"PHASE4":2700,"NA":2702},{"trials":2689,"activeCount":62},[],{"trials":2691,"activeCount":62},[2692],{"nctId":2648,"briefTitle":2649,"status":68,"phases":2693,"primaryCompletion":2651,"completion":2652,"start":2653,"enrollment":2654,"conditions":2694,"interventions":2695},[51],[426,2656,851],[2641,2658,2659],{"trials":2697,"activeCount":62},[],{"trials":2699,"activeCount":62},[],{"trials":2701,"activeCount":62},[],{"trials":2703,"activeCount":62},[],{"intervention":2705,"totalTrials":103,"cells":2706},"IV\u002Foral n-acetylcysteine",{"EARLY_PHASE1":2707,"PHASE1":2709,"PHASE2":2722,"PHASE3":2724,"PHASE4":2726,"NA":2728},{"trials":2708,"activeCount":62},[],{"trials":2710,"activeCount":62},[2711],{"nctId":2712,"briefTitle":2713,"status":68,"phases":2714,"primaryCompletion":2715,"completion":2715,"start":2716,"enrollment":756,"conditions":2717,"interventions":2721},"NCT01878695","Pilot Study of Anti-oxidant Supplementation With N-Acetyl Cysteine in Stage 0\u002FI Breast Cancer",[51],"2015-05-14","2012-07-26",[2718,2719,2720],"Stage 0\u002F1 Breast Cancer","Post Biopsy","Pre-surgery",[2705],{"trials":2723,"activeCount":62},[],{"trials":2725,"activeCount":62},[],{"trials":2727,"activeCount":62},[],{"trials":2729,"activeCount":62},[],{"intervention":2731,"totalTrials":103,"cells":2732},"Samarium-153",{"EARLY_PHASE1":2733,"PHASE1":2735,"PHASE2":2748,"PHASE3":2750,"PHASE4":2752,"NA":2754},{"trials":2734,"activeCount":62},[],{"trials":2736,"activeCount":62},[2737],{"nctId":2738,"briefTitle":2739,"status":68,"phases":2740,"primaryCompletion":2741,"completion":2023,"start":2742,"enrollment":2743,"conditions":2744,"interventions":2745},"NCT00328614","Samarium-153 With Neoadjuvant Hormonal and Radiation Therapy for Locally Advanced Prostate Cancer",[51],"2009-02","2003-03",32,[15],[2731,2746,2747],"Total Androgen Suppression (TAS) with Bicalutamide","Total androgen suppression (TAS) with Goserelin Acetate",{"trials":2749,"activeCount":62},[],{"trials":2751,"activeCount":62},[],{"trials":2753,"activeCount":62},[],{"trials":2755,"activeCount":62},[],{"intervention":2746,"totalTrials":103,"cells":2757},{"EARLY_PHASE1":2758,"PHASE1":2760,"PHASE2":2766,"PHASE3":2768,"PHASE4":2770,"NA":2772},{"trials":2759,"activeCount":62},[],{"trials":2761,"activeCount":62},[2762],{"nctId":2738,"briefTitle":2739,"status":68,"phases":2763,"primaryCompletion":2741,"completion":2023,"start":2742,"enrollment":2743,"conditions":2764,"interventions":2765},[51],[15],[2731,2746,2747],{"trials":2767,"activeCount":62},[],{"trials":2769,"activeCount":62},[],{"trials":2771,"activeCount":62},[],{"trials":2773,"activeCount":62},[],{"intervention":2747,"totalTrials":103,"cells":2775},{"EARLY_PHASE1":2776,"PHASE1":2778,"PHASE2":2784,"PHASE3":2786,"PHASE4":2788,"NA":2790},{"trials":2777,"activeCount":62},[],{"trials":2779,"activeCount":62},[2780],{"nctId":2738,"briefTitle":2739,"status":68,"phases":2781,"primaryCompletion":2741,"completion":2023,"start":2742,"enrollment":2743,"conditions":2782,"interventions":2783},[51],[15],[2731,2746,2747],{"trials":2785,"activeCount":62},[],{"trials":2787,"activeCount":62},[],{"trials":2789,"activeCount":62},[],{"trials":2791,"activeCount":62},[],{"intervention":2793,"totalTrials":103,"cells":2794},"Vemurafenib",{"EARLY_PHASE1":2795,"PHASE1":2797,"PHASE2":2806,"PHASE3":2808,"PHASE4":2810,"NA":2812},{"trials":2796,"activeCount":62},[],{"trials":2798,"activeCount":62},[2799],{"nctId":2800,"briefTitle":2801,"status":680,"phases":2802,"primaryCompletion":2803,"enrollment":62,"conditions":2804,"interventions":2805},"NCT02145910","Vemurafenib Combined With Whole Brain Radiation Therapy or Radiosurgery in Patients With BRAF Mutation-Positive Melanoma and Brain Metastases",[51],"2019-06",[673,674,675],[2793],{"trials":2807,"activeCount":62},[],{"trials":2809,"activeCount":62},[],{"trials":2811,"activeCount":62},[],{"trials":2813,"activeCount":62},[],{"intervention":794,"totalTrials":103,"cells":2815},{"EARLY_PHASE1":2816,"PHASE1":2818,"PHASE2":2824,"PHASE3":2826,"PHASE4":2828,"NA":2830},{"trials":2817,"activeCount":62},[],{"trials":2819,"activeCount":62},[2820],{"nctId":784,"briefTitle":785,"status":331,"phases":2821,"primaryCompletion":787,"completion":788,"start":789,"enrollment":790,"conditions":2822,"interventions":2823},[51],[32,792],[608,794,609],{"trials":2825,"activeCount":62},[],{"trials":2827,"activeCount":62},[],{"trials":2829,"activeCount":62},[],{"trials":2831,"activeCount":62},[],{"intervention":2833,"totalTrials":103,"cells":2834},"Velcade",{"EARLY_PHASE1":2835,"PHASE1":2837,"PHASE2":2848,"PHASE3":2850,"PHASE4":2852,"NA":2854},{"trials":2836,"activeCount":62},[],{"trials":2838,"activeCount":62},[2839],{"nctId":2840,"briefTitle":2841,"status":68,"phases":2842,"primaryCompletion":413,"completion":413,"start":2843,"enrollment":12,"conditions":2844,"interventions":2847},"NCT00329589","A Trial Using Velcade Plus Chemoradiation for Central Nervous System, Head and Neck, and Cervical Cancer Patients",[51],"2005-09",[2845,20,2846,2629],"Brain Cancer","Cervix Cancer",[2833],{"trials":2849,"activeCount":62},[],{"trials":2851,"activeCount":62},[],{"trials":2853,"activeCount":62},[],{"trials":2855,"activeCount":62},[],{"intervention":1190,"totalTrials":103,"cells":2857},{"EARLY_PHASE1":2858,"PHASE1":2860,"PHASE2":2866,"PHASE3":2868,"PHASE4":2870,"NA":2872},{"trials":2859,"activeCount":62},[],{"trials":2861,"activeCount":62},[2862],{"nctId":1180,"briefTitle":1181,"status":68,"phases":2863,"primaryCompletion":413,"completion":413,"start":1183,"enrollment":756,"conditions":2864,"interventions":2865},[51],[20,1185,1186,1187,1188],[524,1190,1191,1173],{"trials":2867,"activeCount":62},[],{"trials":2869,"activeCount":62},[],{"trials":2871,"activeCount":62},[],{"trials":2873,"activeCount":62},[],{"intervention":1191,"totalTrials":103,"cells":2875},{"EARLY_PHASE1":2876,"PHASE1":2878,"PHASE2":2884,"PHASE3":2886,"PHASE4":2888,"NA":2890},{"trials":2877,"activeCount":62},[],{"trials":2879,"activeCount":62},[2880],{"nctId":1180,"briefTitle":1181,"status":68,"phases":2881,"primaryCompletion":413,"completion":413,"start":1183,"enrollment":756,"conditions":2882,"interventions":2883},[51],[20,1185,1186,1187,1188],[524,1190,1191,1173],{"trials":2885,"activeCount":62},[],{"trials":2887,"activeCount":62},[],{"trials":2889,"activeCount":62},[],{"trials":2891,"activeCount":62},[],{"intervention":693,"totalTrials":103,"cells":2893},{"EARLY_PHASE1":2894,"PHASE1":2896,"PHASE2":2902,"PHASE3":2904,"PHASE4":2906,"NA":2908},{"trials":2895,"activeCount":62},[],{"trials":2897,"activeCount":62},[2898],{"nctId":678,"briefTitle":679,"status":680,"phases":2899,"primaryCompletion":682,"completion":682,"start":683,"enrollment":62,"conditions":2900,"interventions":2901},[51],[685,686,687,688,689,690,691],[480,693],{"trials":2903,"activeCount":62},[],{"trials":2905,"activeCount":62},[],{"trials":2907,"activeCount":62},[],{"trials":2909,"activeCount":62},[],{"intervention":2911,"totalTrials":103,"cells":2912},"MK-3475",{"EARLY_PHASE1":2913,"PHASE1":2915,"PHASE2":2935,"PHASE3":2937,"PHASE4":2939,"NA":2941},{"trials":2914,"activeCount":62},[],{"trials":2916,"activeCount":62},[2917],{"nctId":2918,"briefTitle":2919,"status":68,"phases":2920,"primaryCompletion":2921,"completion":2922,"start":2923,"enrollment":439,"conditions":2924,"interventions":2934},"NCT02318771","Radiation Therapy and MK-3475 for Patients With Recurrent\u002FMetastatic Head and Neck Cancer, Renal Cell Cancer, Melanoma, and Lung Cancer",[51],"2018-06-05","2021-03-25","2015-02-05",[2925,2926,2927,2928,2929,2930,2931,2932,2933],"Head and Neck Squamous Cell Carcinoma","Metastatic Renal Cell Cancer","Recurrent Head and Neck Carcinoma","Recurrent Lung Carcinoma","Recurrent Renal Cell Carcinoma","Recurrent Skin Carcinoma","Stage III Renal Cell Cancer","Stage IV Lung Cancer","Stage IV Skin Melanoma",[2911],{"trials":2936,"activeCount":62},[],{"trials":2938,"activeCount":62},[],{"trials":2940,"activeCount":62},[],{"trials":2942,"activeCount":62},[],{"intervention":2944,"totalTrials":103,"cells":2945},"Panobinostat",{"EARLY_PHASE1":2946,"PHASE1":2948,"PHASE2":2960,"PHASE3":2962,"PHASE4":2964,"NA":2966},{"trials":2947,"activeCount":62},[],{"trials":2949,"activeCount":62},[2950],{"nctId":2951,"briefTitle":2952,"status":331,"phases":2953,"primaryCompletion":2498,"completion":2954,"start":447,"enrollment":671,"conditions":2955,"interventions":2959},"NCT01324635","Panobinostat and Stereotactic Radiation Therapy in Treating Patients With Brain Tumors",[51],"2016-10",[2956,2957,2958],"Recurrent Glioma","High-grade Meningioma","Brain Metastasis",[2944],{"trials":2961,"activeCount":62},[],{"trials":2963,"activeCount":62},[],{"trials":2965,"activeCount":62},[],{"trials":2967,"activeCount":62},[],{"intervention":2969,"totalTrials":58,"cells":2970},"Metformin",{"EARLY_PHASE1":2971,"PHASE1":2994,"PHASE2":2996,"PHASE3":2998,"PHASE4":3000,"NA":3002},{"trials":2972,"activeCount":62},[2973,2983],{"nctId":2974,"briefTitle":2975,"status":68,"phases":2976,"primaryCompletion":2977,"completion":2978,"start":2979,"enrollment":488,"conditions":2980,"interventions":2982},"NCT02083692","Pilot Study of Metformin in Head and Neck Squamous Cell Cancer and Its Effects on Stromal-epithelial Metabolic Uncoupling",[50],"2016-05-09","2017-04-06","2013-09-05",[2981],"Head and Neck Squamous Cell Cancer",[2969],{"nctId":2984,"briefTitle":2985,"status":68,"phases":2986,"primaryCompletion":2987,"completion":755,"start":2988,"enrollment":605,"conditions":2989,"interventions":2992},"NCT03618654","Durvalumab With or Without Metformin in Treating Participants With Head and Neck Squamous Cell Carcinoma",[50],"2021-11-20","2018-11-01",[2925,2990,2991],"Oral Cavity Squamous Cell Carcinoma","Oropharyngeal Squamous Cell Carcinoma",[2969,2993],"Durvalumab",{"trials":2995,"activeCount":62},[],{"trials":2997,"activeCount":62},[],{"trials":2999,"activeCount":62},[],{"trials":3001,"activeCount":62},[],{"trials":3003,"activeCount":62},[],{"intervention":3005,"totalTrials":103,"cells":3006},"Perflutren Protein-Type A Microspheres",{"EARLY_PHASE1":3007,"PHASE1":3018,"PHASE2":3020,"PHASE3":3022,"PHASE4":3024,"NA":3026},{"trials":3008,"activeCount":62},[3009],{"nctId":3010,"briefTitle":3011,"status":680,"phases":3012,"primaryCompletion":3013,"completion":3013,"start":3014,"enrollment":62,"conditions":3015,"interventions":3017},"NCT02671552","Contrast-Enhanced Ultrasound in Predicting Treatment Response in Patients With Kidney Cancer Undergoing Cryosurgery",[50],"2014-12-04","2013-01-24",[3016],"Renal Cell Carcinoma",[3005],{"trials":3019,"activeCount":62},[],{"trials":3021,"activeCount":62},[],{"trials":3023,"activeCount":62},[],{"trials":3025,"activeCount":62},[],{"trials":3027,"activeCount":62},[],{"intervention":3029,"totalTrials":103,"cells":3030},"Hyper-CVAD",{"EARLY_PHASE1":3031,"PHASE1":3046,"PHASE2":3048,"PHASE3":3050,"PHASE4":3052,"NA":3054},{"trials":3032,"activeCount":62},[3033],{"nctId":3034,"briefTitle":3035,"status":68,"phases":3036,"primaryCompletion":3037,"completion":3038,"start":268,"enrollment":11,"conditions":3039,"interventions":3045},"NCT01184885","A Pilot Study to Determine the Safety and Tolerability of Sirolimus Given With Hyper-CVAD Chemotherapy",[50],"2011-03","2013-04",[3040,338,3041,3042,3043,3044],"Lymphoid Malignancies (New or Relapsed)","Burkitt Lymphoma","Lymphoblastic Lymphoma","Mantle Cell Lymphoma","Adult T-cell Leukemia\u002FLymphoma",[3029,1372],{"trials":3047,"activeCount":62},[],{"trials":3049,"activeCount":62},[],{"trials":3051,"activeCount":62},[],{"trials":3053,"activeCount":62},[],{"trials":3055,"activeCount":62},[],{"intervention":3057,"totalTrials":103,"cells":3058},"Cesium-131",{"EARLY_PHASE1":3059,"PHASE1":3069,"PHASE2":3071,"PHASE3":3073,"PHASE4":3075,"NA":3077},{"trials":3060,"activeCount":62},[3061],{"nctId":3062,"briefTitle":3063,"status":68,"phases":3064,"primaryCompletion":3065,"completion":3065,"start":3066,"enrollment":176,"conditions":3067,"interventions":3068},"NCT02467738","Surgical Resection and Intraoperative Cesium-131 Brachytherapy for Head and Neck Cancer",[50],"2020-05-28","2015-03-17",[2927],[3057],{"trials":3070,"activeCount":62},[],{"trials":3072,"activeCount":62},[],{"trials":3074,"activeCount":62},[],{"trials":3076,"activeCount":62},[],{"trials":3078,"activeCount":62},[],{"intervention":2993,"totalTrials":103,"cells":3080},{"EARLY_PHASE1":3081,"PHASE1":3087,"PHASE2":3089,"PHASE3":3091,"PHASE4":3093,"NA":3095},{"trials":3082,"activeCount":62},[3083],{"nctId":2984,"briefTitle":2985,"status":68,"phases":3084,"primaryCompletion":2987,"completion":755,"start":2988,"enrollment":605,"conditions":3085,"interventions":3086},[50],[2925,2990,2991],[2969,2993],{"trials":3088,"activeCount":62},[],{"trials":3090,"activeCount":62},[],{"trials":3092,"activeCount":62},[],{"trials":3094,"activeCount":62},[],{"trials":3096,"activeCount":62},[],{"intervention":3098,"totalTrials":103,"cells":3099},"Oxaliplatin",{"EARLY_PHASE1":3100,"PHASE1":3119,"PHASE2":3121,"PHASE3":3123,"PHASE4":3125,"NA":3127},{"trials":3101,"activeCount":62},[3102],{"nctId":3103,"briefTitle":3104,"status":68,"phases":3105,"primaryCompletion":3106,"completion":3107,"start":3108,"enrollment":450,"conditions":3109,"interventions":3115},"NCT02896907","Ascorbic Acid and Combination Chemotherapy in Treating Patients With Locally Advanced or Recurrent Pancreatic Cancer That Cannot Be Removed by Surgery",[50],"2018-03-22","2019-03","2016-10-18",[3110,3111,3112,3113,3114],"Pancreatic Adenocarcinoma","Recurrent Pancreatic Carcinoma","Stage III Pancreatic Cancer","Stage IV Pancreatic Cancer","Unresectable Pancreatic Carcinoma",[3098,3116,3117,3118],"Irinotecan Hydrochloride","Leucovorin Calcium","Fluorouracil",{"trials":3120,"activeCount":62},[],{"trials":3122,"activeCount":62},[],{"trials":3124,"activeCount":62},[],{"trials":3126,"activeCount":62},[],{"trials":3128,"activeCount":62},[],{"intervention":3116,"totalTrials":103,"cells":3130},{"EARLY_PHASE1":3131,"PHASE1":3137,"PHASE2":3139,"PHASE3":3141,"PHASE4":3143,"NA":3145},{"trials":3132,"activeCount":62},[3133],{"nctId":3103,"briefTitle":3104,"status":68,"phases":3134,"primaryCompletion":3106,"completion":3107,"start":3108,"enrollment":450,"conditions":3135,"interventions":3136},[50],[3110,3111,3112,3113,3114],[3098,3116,3117,3118],{"trials":3138,"activeCount":62},[],{"trials":3140,"activeCount":62},[],{"trials":3142,"activeCount":62},[],{"trials":3144,"activeCount":62},[],{"trials":3146,"activeCount":62},[],{"intervention":3117,"totalTrials":103,"cells":3148},{"EARLY_PHASE1":3149,"PHASE1":3155,"PHASE2":3157,"PHASE3":3159,"PHASE4":3161,"NA":3163},{"trials":3150,"activeCount":62},[3151],{"nctId":3103,"briefTitle":3104,"status":68,"phases":3152,"primaryCompletion":3106,"completion":3107,"start":3108,"enrollment":450,"conditions":3153,"interventions":3154},[50],[3110,3111,3112,3113,3114],[3098,3116,3117,3118],{"trials":3156,"activeCount":62},[],{"trials":3158,"activeCount":62},[],{"trials":3160,"activeCount":62},[],{"trials":3162,"activeCount":62},[],{"trials":3164,"activeCount":62},[],{"intervention":3118,"totalTrials":103,"cells":3166},{"EARLY_PHASE1":3167,"PHASE1":3173,"PHASE2":3175,"PHASE3":3177,"PHASE4":3179,"NA":3181},{"trials":3168,"activeCount":62},[3169],{"nctId":3103,"briefTitle":3104,"status":68,"phases":3170,"primaryCompletion":3106,"completion":3107,"start":3108,"enrollment":450,"conditions":3171,"interventions":3172},[50],[3110,3111,3112,3113,3114],[3098,3116,3117,3118],{"trials":3174,"activeCount":62},[],{"trials":3176,"activeCount":62},[],{"trials":3178,"activeCount":62},[],{"trials":3180,"activeCount":62},[],{"trials":3182,"activeCount":62},[],{"intervention":3184,"totalTrials":103,"cells":3185},"Sonazoid",{"EARLY_PHASE1":3186,"PHASE1":3197,"PHASE2":3199,"PHASE3":3201,"PHASE4":3203,"NA":3205},{"trials":3187,"activeCount":62},[3188],{"nctId":3189,"briefTitle":3190,"status":68,"phases":3191,"primaryCompletion":3192,"completion":3192,"start":3193,"enrollment":1156,"conditions":3194,"interventions":3196},"NCT03578224","Contrast-Enhanced Ultrasound Identification of Sentinel Nodes in Esophageal Cancer",[50],"2022-08-25","2018-09-06",[3195],"Esophagus",[3184],{"trials":3198,"activeCount":62},[],{"trials":3200,"activeCount":62},[],{"trials":3202,"activeCount":62},[],{"trials":3204,"activeCount":62},[],{"trials":3206,"activeCount":62},[],{"intervention":491,"totalTrials":103,"cells":3208},{"EARLY_PHASE1":3209,"PHASE1":3215,"PHASE2":3217,"PHASE3":3219,"PHASE4":3221,"NA":3223},{"trials":3210,"activeCount":62},[3211],{"nctId":482,"briefTitle":483,"status":68,"phases":3212,"primaryCompletion":485,"completion":486,"start":487,"enrollment":488,"conditions":3213,"interventions":3214},[50],[478,477],[465,491],{"trials":3216,"activeCount":62},[],{"trials":3218,"activeCount":62},[],{"trials":3220,"activeCount":62},[],{"trials":3222,"activeCount":62},[],{"trials":3224,"activeCount":62},[],{"intervention":325,"totalTrials":2176,"cells":3226},{"EARLY_PHASE1":3227,"PHASE1":3229,"PHASE2":3235,"PHASE3":3303,"PHASE4":3305,"NA":3307},{"trials":3228,"activeCount":62},[],{"trials":3230,"activeCount":62},[3231],{"nctId":1133,"briefTitle":1134,"status":680,"phases":3232,"primaryCompletion":1136,"completion":1137,"start":1138,"enrollment":62,"conditions":3233,"interventions":3234},[51],[1140,1141,1142,1143,1144,1145,1146],[406,1126,325,327,326],{"trials":3236,"activeCount":62},[3237,3241,3245,3249,3259,3263,3267,3271,3275,3279,3283,3287,3291,3299],{"nctId":315,"briefTitle":316,"status":68,"phases":3238,"primaryCompletion":318,"completion":319,"start":320,"enrollment":321,"conditions":3239,"interventions":3240},[52],[323],[306,325,326,327],{"nctId":329,"briefTitle":330,"status":331,"phases":3242,"primaryCompletion":333,"completion":334,"start":335,"enrollment":28,"conditions":3243,"interventions":3244},[52],[323,337,338,339,340,341,32,342,343,344,345,346],[306,325,326,348,349],{"nctId":1036,"briefTitle":1037,"status":68,"phases":3246,"primaryCompletion":1039,"completion":1040,"start":1041,"enrollment":513,"conditions":3247,"interventions":3248},[51,52],[417],[1027,406,1044,325,326,1045,1046],{"nctId":3250,"briefTitle":3251,"status":68,"phases":3252,"primaryCompletion":3253,"completion":3253,"start":3254,"enrollment":3255,"conditions":3256,"interventions":3258},"NCT03032783","A Two Step Approach to Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Hematologic Malignancies-Increasing GVT Effects Without Increasing Toxicity",[52],"2025-12-02","2017-01-31",51,[3257],"Hematopoietic and Lymphoid Cell Neoplasm",[325,326,348],{"nctId":351,"briefTitle":352,"status":68,"phases":3260,"primaryCompletion":354,"completion":355,"start":356,"enrollment":357,"conditions":3261,"interventions":3262},[52],[359,360,361,362,363,364,365,366,367,368,369,370,371,372,373,374,375,376,377,378,379,380,381,382,383,384,30,385,386,387,388,389,390,391,392,393,394,395,396,397,398,399,400,401,402,403,404],[406,407,306,325,326,327],{"nctId":613,"briefTitle":614,"status":68,"phases":3264,"primaryCompletion":616,"completion":617,"start":618,"enrollment":8,"conditions":3265,"interventions":3266},[52],[620,621,622,623,624,625,626,627],[571,572,629,325,630],{"nctId":820,"briefTitle":821,"status":68,"phases":3268,"primaryCompletion":823,"completion":755,"start":824,"enrollment":825,"conditions":3269,"interventions":3270},[52],[827],[325,326,327,406,407,829],{"nctId":409,"briefTitle":410,"status":68,"phases":3272,"primaryCompletion":412,"completion":413,"start":414,"enrollment":415,"conditions":3273,"interventions":3274},[51,52],[417],[306,325,326,348,349],{"nctId":1769,"briefTitle":1770,"status":331,"phases":3276,"primaryCompletion":1772,"completion":1773,"start":1774,"enrollment":28,"conditions":3277,"interventions":3278},[52],[23],[1760,325,326,327],{"nctId":1151,"briefTitle":1152,"status":68,"phases":3280,"primaryCompletion":1154,"completion":1154,"start":1155,"enrollment":1156,"conditions":3281,"interventions":3282},[52],[426,1158,368,373,845,1159,23,846,1160,850,397,1161,1162,1163,1164],[406,1126,325,326,327],{"nctId":420,"briefTitle":421,"status":68,"phases":3284,"primaryCompletion":334,"completion":423,"start":268,"enrollment":424,"conditions":3285,"interventions":3286},[52],[426,427,428,429,430,32,431,343,432,368],[306,325,348,326],{"nctId":435,"briefTitle":436,"status":68,"phases":3288,"primaryCompletion":438,"completion":438,"start":318,"enrollment":439,"conditions":3289,"interventions":3290},[52],[441],[306,325,327],{"nctId":3292,"briefTitle":3293,"status":68,"phases":3294,"primaryCompletion":3295,"completion":3295,"start":3296,"enrollment":790,"conditions":3297,"interventions":3298},"NCT03712878","2-Step Approach to Stem Cell Transplant in Treating Participants With Hematological Malignancies",[52],"2025-03-19","2018-09-19",[3257],[325,326,348],{"nctId":831,"briefTitle":832,"status":68,"phases":3300,"primaryCompletion":834,"completion":835,"start":836,"enrollment":837,"conditions":3301,"interventions":3302},[52],[839,840,841,842,368,32,843,373,844,845,846,847,848,849,850,381,30,389,851,852,853],[855,407,856,325,326,348],{"trials":3304,"activeCount":62},[],{"trials":3306,"activeCount":62},[],{"trials":3308,"activeCount":62},[3309],{"nctId":3310,"briefTitle":3311,"status":331,"phases":3312,"primaryCompletion":3313,"completion":3313,"start":3314,"enrollment":58,"conditions":3315,"interventions":3319},"NCT01350232","Treatment of Sickle Cell Anemia With Stem Cell Transplant",[55],"2011-08","2009-09",[3316,3317,3318],"Sickle Cell Anemia","Sickle Cell-hemoglobin C Disease","Sickle Cell-β0-thalassemia",[406,1044,325,997,1849],{"intervention":326,"totalTrials":513,"cells":3321},{"EARLY_PHASE1":3322,"PHASE1":3324,"PHASE2":3330,"PHASE3":3380,"PHASE4":3382,"NA":3384},{"trials":3323,"activeCount":62},[],{"trials":3325,"activeCount":62},[3326],{"nctId":1133,"briefTitle":1134,"status":680,"phases":3327,"primaryCompletion":1136,"completion":1137,"start":1138,"enrollment":62,"conditions":3328,"interventions":3329},[51],[1140,1141,1142,1143,1144,1145,1146],[406,1126,325,327,326],{"trials":3331,"activeCount":62},[3332,3336,3340,3344,3348,3352,3356,3360,3364,3368,3372,3376],{"nctId":315,"briefTitle":316,"status":68,"phases":3333,"primaryCompletion":318,"completion":319,"start":320,"enrollment":321,"conditions":3334,"interventions":3335},[52],[323],[306,325,326,327],{"nctId":329,"briefTitle":330,"status":331,"phases":3337,"primaryCompletion":333,"completion":334,"start":335,"enrollment":28,"conditions":3338,"interventions":3339},[52],[323,337,338,339,340,341,32,342,343,344,345,346],[306,325,326,348,349],{"nctId":1036,"briefTitle":1037,"status":68,"phases":3341,"primaryCompletion":1039,"completion":1040,"start":1041,"enrollment":513,"conditions":3342,"interventions":3343},[51,52],[417],[1027,406,1044,325,326,1045,1046],{"nctId":3250,"briefTitle":3251,"status":68,"phases":3345,"primaryCompletion":3253,"completion":3253,"start":3254,"enrollment":3255,"conditions":3346,"interventions":3347},[52],[3257],[325,326,348],{"nctId":351,"briefTitle":352,"status":68,"phases":3349,"primaryCompletion":354,"completion":355,"start":356,"enrollment":357,"conditions":3350,"interventions":3351},[52],[359,360,361,362,363,364,365,366,367,368,369,370,371,372,373,374,375,376,377,378,379,380,381,382,383,384,30,385,386,387,388,389,390,391,392,393,394,395,396,397,398,399,400,401,402,403,404],[406,407,306,325,326,327],{"nctId":820,"briefTitle":821,"status":68,"phases":3353,"primaryCompletion":823,"completion":755,"start":824,"enrollment":825,"conditions":3354,"interventions":3355},[52],[827],[325,326,327,406,407,829],{"nctId":409,"briefTitle":410,"status":68,"phases":3357,"primaryCompletion":412,"completion":413,"start":414,"enrollment":415,"conditions":3358,"interventions":3359},[51,52],[417],[306,325,326,348,349],{"nctId":1769,"briefTitle":1770,"status":331,"phases":3361,"primaryCompletion":1772,"completion":1773,"start":1774,"enrollment":28,"conditions":3362,"interventions":3363},[52],[23],[1760,325,326,327],{"nctId":1151,"briefTitle":1152,"status":68,"phases":3365,"primaryCompletion":1154,"completion":1154,"start":1155,"enrollment":1156,"conditions":3366,"interventions":3367},[52],[426,1158,368,373,845,1159,23,846,1160,850,397,1161,1162,1163,1164],[406,1126,325,326,327],{"nctId":420,"briefTitle":421,"status":68,"phases":3369,"primaryCompletion":334,"completion":423,"start":268,"enrollment":424,"conditions":3370,"interventions":3371},[52],[426,427,428,429,430,32,431,343,432,368],[306,325,348,326],{"nctId":3292,"briefTitle":3293,"status":68,"phases":3373,"primaryCompletion":3295,"completion":3295,"start":3296,"enrollment":790,"conditions":3374,"interventions":3375},[52],[3257],[325,326,348],{"nctId":831,"briefTitle":832,"status":68,"phases":3377,"primaryCompletion":834,"completion":835,"start":836,"enrollment":837,"conditions":3378,"interventions":3379},[52],[839,840,841,842,368,32,843,373,844,845,846,847,848,849,850,381,30,389,851,852,853],[855,407,856,325,326,348],{"trials":3381,"activeCount":62},[],{"trials":3383,"activeCount":62},[],{"trials":3385,"activeCount":62},[3386],{"nctId":3387,"briefTitle":3388,"status":680,"phases":3389,"primaryCompletion":3314,"completion":3314,"start":3390,"enrollment":62,"conditions":3391,"interventions":3394},"NCT00203281","Study to Evaluate the Amount of Medications That May be Removed From the Body During Plasmapheresis",[],"2003-02",[3392,3393],"Kidney Transplantation","Plasmapheresis",[3395,3396,3397,3398],"tacrolimus","mycophenolate mofetil","daclizumab","intravenous immune globulin",{"intervention":327,"totalTrials":513,"cells":3400},{"EARLY_PHASE1":3401,"PHASE1":3403,"PHASE2":3409,"PHASE3":3459,"PHASE4":3461,"NA":3463},{"trials":3402,"activeCount":62},[],{"trials":3404,"activeCount":62},[3405],{"nctId":1133,"briefTitle":1134,"status":680,"phases":3406,"primaryCompletion":1136,"completion":1137,"start":1138,"enrollment":62,"conditions":3407,"interventions":3408},[51],[1140,1141,1142,1143,1144,1145,1146],[406,1126,325,327,326],{"trials":3410,"activeCount":62},[3411,3415,3419,3423,3427,3431,3435,3439,3443,3447,3451,3455],{"nctId":315,"briefTitle":316,"status":68,"phases":3412,"primaryCompletion":318,"completion":319,"start":320,"enrollment":321,"conditions":3413,"interventions":3414},[52],[323],[306,325,326,327],{"nctId":329,"briefTitle":330,"status":331,"phases":3416,"primaryCompletion":333,"completion":334,"start":335,"enrollment":28,"conditions":3417,"interventions":3418},[52],[323,337,338,339,340,341,32,342,343,344,345,346],[306,325,326,348,349],{"nctId":3250,"briefTitle":3251,"status":68,"phases":3420,"primaryCompletion":3253,"completion":3253,"start":3254,"enrollment":3255,"conditions":3421,"interventions":3422},[52],[3257],[325,326,348],{"nctId":351,"briefTitle":352,"status":68,"phases":3424,"primaryCompletion":354,"completion":355,"start":356,"enrollment":357,"conditions":3425,"interventions":3426},[52],[359,360,361,362,363,364,365,366,367,368,369,370,371,372,373,374,375,376,377,378,379,380,381,382,383,384,30,385,386,387,388,389,390,391,392,393,394,395,396,397,398,399,400,401,402,403,404],[406,407,306,325,326,327],{"nctId":820,"briefTitle":821,"status":68,"phases":3428,"primaryCompletion":823,"completion":755,"start":824,"enrollment":825,"conditions":3429,"interventions":3430},[52],[827],[325,326,327,406,407,829],{"nctId":409,"briefTitle":410,"status":68,"phases":3432,"primaryCompletion":412,"completion":413,"start":414,"enrollment":415,"conditions":3433,"interventions":3434},[51,52],[417],[306,325,326,348,349],{"nctId":1769,"briefTitle":1770,"status":331,"phases":3436,"primaryCompletion":1772,"completion":1773,"start":1774,"enrollment":28,"conditions":3437,"interventions":3438},[52],[23],[1760,325,326,327],{"nctId":1151,"briefTitle":1152,"status":68,"phases":3440,"primaryCompletion":1154,"completion":1154,"start":1155,"enrollment":1156,"conditions":3441,"interventions":3442},[52],[426,1158,368,373,845,1159,23,846,1160,850,397,1161,1162,1163,1164],[406,1126,325,326,327],{"nctId":420,"briefTitle":421,"status":68,"phases":3444,"primaryCompletion":334,"completion":423,"start":268,"enrollment":424,"conditions":3445,"interventions":3446},[52],[426,427,428,429,430,32,431,343,432,368],[306,325,348,326],{"nctId":435,"briefTitle":436,"status":68,"phases":3448,"primaryCompletion":438,"completion":438,"start":318,"enrollment":439,"conditions":3449,"interventions":3450},[52],[441],[306,325,327],{"nctId":3292,"briefTitle":3293,"status":68,"phases":3452,"primaryCompletion":3295,"completion":3295,"start":3296,"enrollment":790,"conditions":3453,"interventions":3454},[52],[3257],[325,326,348],{"nctId":831,"briefTitle":832,"status":68,"phases":3456,"primaryCompletion":834,"completion":835,"start":836,"enrollment":837,"conditions":3457,"interventions":3458},[52],[839,840,841,842,368,32,843,373,844,845,846,847,848,849,850,381,30,389,851,852,853],[855,407,856,325,326,348],{"trials":3460,"activeCount":62},[],{"trials":3462,"activeCount":62},[],{"trials":3464,"activeCount":62},[3465],{"nctId":3387,"briefTitle":3388,"status":680,"phases":3466,"primaryCompletion":3314,"completion":3314,"start":3390,"enrollment":62,"conditions":3467,"interventions":3468},[],[3392,3393],[3395,3396,3397,3398],{"intervention":406,"totalTrials":11,"cells":3470},{"EARLY_PHASE1":3471,"PHASE1":3473,"PHASE2":3479,"PHASE3":3501,"PHASE4":3503,"NA":3505},{"trials":3472,"activeCount":62},[],{"trials":3474,"activeCount":62},[3475],{"nctId":1133,"briefTitle":1134,"status":680,"phases":3476,"primaryCompletion":1136,"completion":1137,"start":1138,"enrollment":62,"conditions":3477,"interventions":3478},[51],[1140,1141,1142,1143,1144,1145,1146],[406,1126,325,327,326],{"trials":3480,"activeCount":62},[3481,3485,3489,3493,3497],{"nctId":1036,"briefTitle":1037,"status":68,"phases":3482,"primaryCompletion":1039,"completion":1040,"start":1041,"enrollment":513,"conditions":3483,"interventions":3484},[51,52],[417],[1027,406,1044,325,326,1045,1046],{"nctId":351,"briefTitle":352,"status":68,"phases":3486,"primaryCompletion":354,"completion":355,"start":356,"enrollment":357,"conditions":3487,"interventions":3488},[52],[359,360,361,362,363,364,365,366,367,368,369,370,371,372,373,374,375,376,377,378,379,380,381,382,383,384,30,385,386,387,388,389,390,391,392,393,394,395,396,397,398,399,400,401,402,403,404],[406,407,306,325,326,327],{"nctId":820,"briefTitle":821,"status":68,"phases":3490,"primaryCompletion":823,"completion":755,"start":824,"enrollment":825,"conditions":3491,"interventions":3492},[52],[827],[325,326,327,406,407,829],{"nctId":1151,"briefTitle":1152,"status":68,"phases":3494,"primaryCompletion":1154,"completion":1154,"start":1155,"enrollment":1156,"conditions":3495,"interventions":3496},[52],[426,1158,368,373,845,1159,23,846,1160,850,397,1161,1162,1163,1164],[406,1126,325,326,327],{"nctId":444,"briefTitle":445,"status":331,"phases":3498,"primaryCompletion":447,"completion":448,"start":449,"enrollment":450,"conditions":3499,"interventions":3500},[51,52],[417,452,453,344,27,346,454],[406,456,306,457],{"trials":3502,"activeCount":62},[],{"trials":3504,"activeCount":62},[],{"trials":3506,"activeCount":62},[3507],{"nctId":3310,"briefTitle":3311,"status":331,"phases":3508,"primaryCompletion":3313,"completion":3313,"start":3314,"enrollment":58,"conditions":3509,"interventions":3510},[55],[3316,3317,3318],[406,1044,325,997,1849],{"intervention":1044,"totalTrials":9,"cells":3512},{"EARLY_PHASE1":3513,"PHASE1":3519,"PHASE2":3525,"PHASE3":3541,"PHASE4":3543,"NA":3545},{"trials":3514,"activeCount":62},[3515],{"nctId":2349,"briefTitle":2350,"status":68,"phases":3516,"primaryCompletion":2352,"completion":2352,"start":2353,"enrollment":1935,"conditions":3517,"interventions":3518},[50],[2355,2356,2357,2358,2359,361,362,363,365,366,2360,2361,2362,2363],[1372,2365,1044],{"trials":3520,"activeCount":62},[3521],{"nctId":1216,"briefTitle":1217,"status":68,"phases":3522,"completion":1219,"start":1220,"conditions":3523,"interventions":3524},[51],[642,337],[645,1223,1224],{"trials":3526,"activeCount":62},[3527,3531],{"nctId":1036,"briefTitle":1037,"status":68,"phases":3528,"primaryCompletion":1039,"completion":1040,"start":1041,"enrollment":513,"conditions":3529,"interventions":3530},[51,52],[417],[1027,406,1044,325,326,1045,1046],{"nctId":3532,"briefTitle":3533,"status":68,"phases":3534,"primaryCompletion":3535,"completion":3536,"start":3537,"enrollment":72,"conditions":3538,"interventions":3539},"NCT02583893","Biomarkers in Predicting Treatment Response to Sirolimus and Chemotherapy in Patients With High-Risk Acute Myeloid Leukemia",[52],"2023-04-17","2023-05-17","2015-10-07",[30,852,2363],[1372,3540,610,1044],"Mitoxantrone",{"trials":3542,"activeCount":62},[],{"trials":3544,"activeCount":62},[],{"trials":3546,"activeCount":62},[3547,3551],{"nctId":3310,"briefTitle":3311,"status":331,"phases":3548,"primaryCompletion":3313,"completion":3313,"start":3314,"enrollment":58,"conditions":3549,"interventions":3550},[55],[3316,3317,3318],[406,1044,325,997,1849],{"nctId":3552,"briefTitle":3553,"status":68,"phases":3554,"primaryCompletion":2427,"completion":3555,"start":268,"enrollment":3556,"conditions":3557,"interventions":3558},"NCT01184898","Pilot Trial of Sirolimus\u002FMEC in High Risk Acute Myelogenous Leukemia (AML)",[55],"2016-02",36,[341],[1372,3540,610,1044],{"intervention":1372,"totalTrials":21,"cells":3560},{"EARLY_PHASE1":3561,"PHASE1":3571,"PHASE2":3573,"PHASE3":3583,"PHASE4":3585,"NA":3587},{"trials":3562,"activeCount":62},[3563,3567],{"nctId":3034,"briefTitle":3035,"status":68,"phases":3564,"primaryCompletion":3037,"completion":3038,"start":268,"enrollment":11,"conditions":3565,"interventions":3566},[50],[3040,338,3041,3042,3043,3044],[3029,1372],{"nctId":2349,"briefTitle":2350,"status":68,"phases":3568,"primaryCompletion":2352,"completion":2352,"start":2353,"enrollment":1935,"conditions":3569,"interventions":3570},[50],[2355,2356,2357,2358,2359,361,362,363,365,366,2360,2361,2362,2363],[1372,2365,1044],{"trials":3572,"activeCount":62},[],{"trials":3574,"activeCount":62},[3575,3579],{"nctId":1362,"briefTitle":1363,"status":68,"phases":3576,"primaryCompletion":1365,"completion":1365,"start":1366,"enrollment":1367,"conditions":3577,"interventions":3578},[52],[361,362,363,364,365,366,1369,1370,382,30],[1372,1353],{"nctId":3532,"briefTitle":3533,"status":68,"phases":3580,"primaryCompletion":3535,"completion":3536,"start":3537,"enrollment":72,"conditions":3581,"interventions":3582},[52],[30,852,2363],[1372,3540,610,1044],{"trials":3584,"activeCount":62},[],{"trials":3586,"activeCount":62},[],{"trials":3588,"activeCount":62},[3589],{"nctId":3552,"briefTitle":3553,"status":68,"phases":3590,"primaryCompletion":2427,"completion":3555,"start":268,"enrollment":3556,"conditions":3591,"interventions":3592},[55],[341],[1372,3540,610,1044],{"intervention":524,"totalTrials":28,"cells":3594},{"EARLY_PHASE1":3595,"PHASE1":3597,"PHASE2":3603,"PHASE3":3609,"PHASE4":3611,"NA":3613},{"trials":3596,"activeCount":62},[],{"trials":3598,"activeCount":62},[3599],{"nctId":1180,"briefTitle":1181,"status":68,"phases":3600,"primaryCompletion":413,"completion":413,"start":1183,"enrollment":756,"conditions":3601,"interventions":3602},[51],[20,1185,1186,1187,1188],[524,1190,1191,1173],{"trials":3604,"activeCount":62},[3605],{"nctId":507,"briefTitle":508,"status":331,"phases":3606,"primaryCompletion":510,"completion":511,"start":512,"enrollment":513,"conditions":3607,"interventions":3608},[52],[515,516,517,518,519,520,521,522],[465,524,525,526],{"trials":3610,"activeCount":62},[],{"trials":3612,"activeCount":62},[],{"trials":3614,"activeCount":62},[3615,3625],{"nctId":3616,"briefTitle":3617,"status":331,"phases":3618,"primaryCompletion":3619,"completion":3620,"start":3621,"enrollment":103,"conditions":3622,"interventions":3623},"NCT01369641","The Effect of Sodium Thiosulfate Eardrops on Hearing Loss in Patients Who Receive Cisplatin Therapy",[55],"2013-03-10","2013-05-02","2011-08-24",[74],[3624,524],"Sodium Thiosulfate",{"nctId":3626,"briefTitle":3627,"status":680,"phases":3628,"primaryCompletion":3629,"completion":3629,"start":3630,"enrollment":62,"conditions":3631,"interventions":3632},"NCT01326468","Torisel in Addition to Standard Chemotherapy With Radiation for Advanced Head and Neck Cancer",[55],"2016-12","2011-12-08",[20],[3633,3634,524],"Temsirolimus","Cetuximab",{"intervention":610,"totalTrials":767,"cells":3636},{"EARLY_PHASE1":3637,"PHASE1":3639,"PHASE2":3641,"PHASE3":3651,"PHASE4":3653,"NA":3655},{"trials":3638,"activeCount":62},[],{"trials":3640,"activeCount":62},[],{"trials":3642,"activeCount":62},[3643,3647],{"nctId":599,"briefTitle":600,"status":68,"phases":3644,"primaryCompletion":602,"completion":603,"start":604,"enrollment":605,"conditions":3645,"interventions":3646},[51,52],[27],[608,609,572,610,611],{"nctId":3532,"briefTitle":3533,"status":68,"phases":3648,"primaryCompletion":3535,"completion":3536,"start":3537,"enrollment":72,"conditions":3649,"interventions":3650},[52],[30,852,2363],[1372,3540,610,1044],{"trials":3652,"activeCount":62},[],{"trials":3654,"activeCount":62},[],{"trials":3656,"activeCount":62},[3657],{"nctId":3552,"briefTitle":3553,"status":68,"phases":3658,"primaryCompletion":2427,"completion":3555,"start":268,"enrollment":3556,"conditions":3659,"interventions":3660},[55],[341],[1372,3540,610,1044],{"intervention":997,"totalTrials":767,"cells":3662},{"EARLY_PHASE1":3663,"PHASE1":3665,"PHASE2":3667,"PHASE3":3682,"PHASE4":3684,"NA":3686},{"trials":3664,"activeCount":62},[],{"trials":3666,"activeCount":62},[],{"trials":3668,"activeCount":62},[3669,3673],{"nctId":985,"briefTitle":986,"status":68,"phases":3670,"primaryCompletion":988,"completion":989,"start":990,"enrollment":475,"conditions":3671,"interventions":3672},[52],[992,993,994],[996,997,964],{"nctId":3674,"briefTitle":3675,"status":68,"phases":3676,"primaryCompletion":3677,"completion":3314,"start":3678,"enrollment":16,"conditions":3679,"interventions":3681},"NCT00408928","Study on the Safety and Effectiveness of VELCADE® in the Treatment of Graft-Versus-Host Disease",[52],"2008-09","2005-11",[3680],"Graft-versus-Host Disease",[997],{"trials":3683,"activeCount":62},[],{"trials":3685,"activeCount":62},[],{"trials":3687,"activeCount":62},[3688],{"nctId":3310,"briefTitle":3311,"status":331,"phases":3689,"primaryCompletion":3313,"completion":3313,"start":3314,"enrollment":58,"conditions":3690,"interventions":3691},[55],[3316,3317,3318],[406,1044,325,997,1849],{"intervention":3693,"totalTrials":58,"cells":3694},"Copper Cu 64 TP3805",{"EARLY_PHASE1":3695,"PHASE1":3707,"PHASE2":3709,"PHASE3":3711,"PHASE4":3713,"NA":3715},{"trials":3696,"activeCount":62},[3697],{"nctId":3698,"briefTitle":3699,"status":68,"phases":3700,"primaryCompletion":3701,"completion":3702,"start":3703,"enrollment":1100,"conditions":3704,"interventions":3706},"NCT03039413","Copper Cu-64 TP3805 PET\u002FCT in Imaging Patients With Urothelial Cancer Undergoing Surgery or Biopsy",[50],"2019-05-21","2024-07-19","2016-09-28",[3705,1115],"Bladder Urothelial Carcinoma",[3693],{"trials":3708,"activeCount":62},[],{"trials":3710,"activeCount":62},[],{"trials":3712,"activeCount":62},[],{"trials":3714,"activeCount":62},[],{"trials":3716,"activeCount":62},[3717],{"nctId":3718,"briefTitle":3719,"status":331,"phases":3720,"primaryCompletion":447,"completion":3721,"start":3677,"enrollment":3722,"conditions":3723,"interventions":3724},"NCT02810873","Positron Emission Tomography Imaging Using Copper Cu 64 TP3805 in Patients With Breast Cancer",[55],"2012-07",19,[25],[3693],{"intervention":3540,"totalTrials":58,"cells":3726},{"EARLY_PHASE1":3727,"PHASE1":3729,"PHASE2":3731,"PHASE3":3737,"PHASE4":3739,"NA":3741},{"trials":3728,"activeCount":62},[],{"trials":3730,"activeCount":62},[],{"trials":3732,"activeCount":62},[3733],{"nctId":3532,"briefTitle":3533,"status":68,"phases":3734,"primaryCompletion":3535,"completion":3536,"start":3537,"enrollment":72,"conditions":3735,"interventions":3736},[52],[30,852,2363],[1372,3540,610,1044],{"trials":3738,"activeCount":62},[],{"trials":3740,"activeCount":62},[],{"trials":3742,"activeCount":62},[3743],{"nctId":3552,"briefTitle":3553,"status":68,"phases":3744,"primaryCompletion":2427,"completion":3555,"start":268,"enrollment":3556,"conditions":3745,"interventions":3746},[55],[341],[1372,3540,610,1044],{"intervention":1849,"totalTrials":58,"cells":3748},{"EARLY_PHASE1":3749,"PHASE1":3751,"PHASE2":3753,"PHASE3":3759,"PHASE4":3761,"NA":3763},{"trials":3750,"activeCount":62},[],{"trials":3752,"activeCount":62},[],{"trials":3754,"activeCount":62},[3755],{"nctId":1840,"briefTitle":1841,"status":68,"phases":3756,"primaryCompletion":1843,"completion":1844,"start":1845,"enrollment":16,"conditions":3757,"interventions":3758},[52],[1847],[1849,1831],{"trials":3760,"activeCount":62},[],{"trials":3762,"activeCount":62},[],{"trials":3764,"activeCount":62},[3765],{"nctId":3310,"briefTitle":3311,"status":331,"phases":3766,"primaryCompletion":3313,"completion":3313,"start":3314,"enrollment":58,"conditions":3767,"interventions":3768},[55],[3316,3317,3318],[406,1044,325,997,1849],{"intervention":3770,"totalTrials":103,"cells":3771},"Contrast Enhanced-Transrectal Ultrasound",{"EARLY_PHASE1":3772,"PHASE1":3774,"PHASE2":3776,"PHASE3":3778,"PHASE4":3780,"NA":3782},{"trials":3773,"activeCount":62},[],{"trials":3775,"activeCount":62},[],{"trials":3777,"activeCount":62},[],{"trials":3779,"activeCount":62},[],{"trials":3781,"activeCount":62},[],{"trials":3783,"activeCount":62},[3784],{"nctId":3785,"briefTitle":3786,"status":331,"phases":3787,"primaryCompletion":3788,"completion":3788,"start":3789,"enrollment":103,"conditions":3790,"interventions":3791},"NCT00635167","Contrast Enhanced Transrectal Ultrasonography (TRUS) to Assess Prostatic Vascularity After Radiotherapy (XRT)",[55],"2011-05-12","2007-06",[15],[3770],{"intervention":3624,"totalTrials":103,"cells":3793},{"EARLY_PHASE1":3794,"PHASE1":3796,"PHASE2":3798,"PHASE3":3800,"PHASE4":3802,"NA":3804},{"trials":3795,"activeCount":62},[],{"trials":3797,"activeCount":62},[],{"trials":3799,"activeCount":62},[],{"trials":3801,"activeCount":62},[],{"trials":3803,"activeCount":62},[],{"trials":3805,"activeCount":62},[3806],{"nctId":3616,"briefTitle":3617,"status":331,"phases":3807,"primaryCompletion":3619,"completion":3620,"start":3621,"enrollment":103,"conditions":3808,"interventions":3809},[55],[74],[3624,524],{"intervention":3811,"totalTrials":103,"cells":3812},"Allogeneic hematopoietic stem cell transplantation",{"EARLY_PHASE1":3813,"PHASE1":3815,"PHASE2":3817,"PHASE3":3819,"PHASE4":3821,"NA":3823},{"trials":3814,"activeCount":62},[],{"trials":3816,"activeCount":62},[],{"trials":3818,"activeCount":62},[],{"trials":3820,"activeCount":62},[],{"trials":3822,"activeCount":62},[],{"trials":3824,"activeCount":62},[3825],{"nctId":3826,"briefTitle":3827,"status":680,"phases":3828,"primaryCompletion":3829,"completion":3829,"start":448,"enrollment":62,"conditions":3830,"interventions":3835},"NCT01660347","Donor Stem Cell Boost in Treating Patients With Low Blood Cells After Donor Stem Cell Transplant",[55],"2014-12",[3831,441,3832,3833,3834],"Anemia","Lymphopenia","Neutropenia","Thrombocytopenia",[3811,3836],"Peripheral blood stem cell transplantation",{"intervention":3836,"totalTrials":103,"cells":3838},{"EARLY_PHASE1":3839,"PHASE1":3841,"PHASE2":3843,"PHASE3":3845,"PHASE4":3847,"NA":3849},{"trials":3840,"activeCount":62},[],{"trials":3842,"activeCount":62},[],{"trials":3844,"activeCount":62},[],{"trials":3846,"activeCount":62},[],{"trials":3848,"activeCount":62},[],{"trials":3850,"activeCount":62},[3851],{"nctId":3826,"briefTitle":3827,"status":680,"phases":3852,"primaryCompletion":3829,"completion":3829,"start":448,"enrollment":62,"conditions":3853,"interventions":3854},[55],[3831,441,3832,3833,3834],[3811,3836],{"intervention":3397,"totalTrials":103,"cells":3856},{"EARLY_PHASE1":3857,"PHASE1":3859,"PHASE2":3861,"PHASE3":3863,"PHASE4":3865,"NA":3867},{"trials":3858,"activeCount":62},[],{"trials":3860,"activeCount":62},[],{"trials":3862,"activeCount":62},[],{"trials":3864,"activeCount":62},[],{"trials":3866,"activeCount":62},[],{"trials":3868,"activeCount":62},[3869],{"nctId":3387,"briefTitle":3388,"status":680,"phases":3870,"primaryCompletion":3314,"completion":3314,"start":3390,"enrollment":62,"conditions":3871,"interventions":3872},[],[3392,3393],[3395,3396,3397,3398],{"intervention":3398,"totalTrials":103,"cells":3874},{"EARLY_PHASE1":3875,"PHASE1":3877,"PHASE2":3879,"PHASE3":3881,"PHASE4":3883,"NA":3885},{"trials":3876,"activeCount":62},[],{"trials":3878,"activeCount":62},[],{"trials":3880,"activeCount":62},[],{"trials":3882,"activeCount":62},[],{"trials":3884,"activeCount":62},[],{"trials":3886,"activeCount":62},[3887],{"nctId":3387,"briefTitle":3388,"status":680,"phases":3888,"primaryCompletion":3314,"completion":3314,"start":3390,"enrollment":62,"conditions":3889,"interventions":3890},[],[3392,3393],[3395,3396,3397,3398],{"intervention":3892,"totalTrials":103,"cells":3893},"cytogenetic analysis",{"EARLY_PHASE1":3894,"PHASE1":3896,"PHASE2":3898,"PHASE3":3900,"PHASE4":3902,"NA":3904},{"trials":3895,"activeCount":62},[],{"trials":3897,"activeCount":62},[],{"trials":3899,"activeCount":62},[],{"trials":3901,"activeCount":62},[],{"trials":3903,"activeCount":62},[],{"trials":3905,"activeCount":62},[3906],{"nctId":3907,"briefTitle":3908,"status":1493,"phases":3909,"start":2742,"enrollment":3910,"conditions":3911,"interventions":3912},"NCT00898690","Gene Expression in Predicting Response to Paclitaxel in Patients With Breast Cancer",[],120,[18],[3892,3913,3914,3915,3916],"gene expression analysis","microarray analysis","mutation analysis","reverse transcriptase-polymerase chain reaction",{"intervention":3913,"totalTrials":103,"cells":3918},{"EARLY_PHASE1":3919,"PHASE1":3921,"PHASE2":3923,"PHASE3":3925,"PHASE4":3927,"NA":3929},{"trials":3920,"activeCount":62},[],{"trials":3922,"activeCount":62},[],{"trials":3924,"activeCount":62},[],{"trials":3926,"activeCount":62},[],{"trials":3928,"activeCount":62},[],{"trials":3930,"activeCount":62},[3931],{"nctId":3907,"briefTitle":3908,"status":1493,"phases":3932,"start":2742,"enrollment":3910,"conditions":3933,"interventions":3934},[],[18],[3892,3913,3914,3915,3916],{"intervention":3914,"totalTrials":103,"cells":3936},{"EARLY_PHASE1":3937,"PHASE1":3939,"PHASE2":3941,"PHASE3":3943,"PHASE4":3945,"NA":3947},{"trials":3938,"activeCount":62},[],{"trials":3940,"activeCount":62},[],{"trials":3942,"activeCount":62},[],{"trials":3944,"activeCount":62},[],{"trials":3946,"activeCount":62},[],{"trials":3948,"activeCount":62},[3949],{"nctId":3907,"briefTitle":3908,"status":1493,"phases":3950,"start":2742,"enrollment":3910,"conditions":3951,"interventions":3952},[],[18],[3892,3913,3914,3915,3916],{"intervention":3915,"totalTrials":103,"cells":3954},{"EARLY_PHASE1":3955,"PHASE1":3957,"PHASE2":3959,"PHASE3":3961,"PHASE4":3963,"NA":3965},{"trials":3956,"activeCount":62},[],{"trials":3958,"activeCount":62},[],{"trials":3960,"activeCount":62},[],{"trials":3962,"activeCount":62},[],{"trials":3964,"activeCount":62},[],{"trials":3966,"activeCount":62},[3967],{"nctId":3907,"briefTitle":3908,"status":1493,"phases":3968,"start":2742,"enrollment":3910,"conditions":3969,"interventions":3970},[],[18],[3892,3913,3914,3915,3916],{"intervention":3916,"totalTrials":103,"cells":3972},{"EARLY_PHASE1":3973,"PHASE1":3975,"PHASE2":3977,"PHASE3":3979,"PHASE4":3981,"NA":3983},{"trials":3974,"activeCount":62},[],{"trials":3976,"activeCount":62},[],{"trials":3978,"activeCount":62},[],{"trials":3980,"activeCount":62},[],{"trials":3982,"activeCount":62},[],{"trials":3984,"activeCount":62},[3985],{"nctId":3907,"briefTitle":3908,"status":1493,"phases":3986,"start":2742,"enrollment":3910,"conditions":3987,"interventions":3988},[],[18],[3892,3913,3914,3915,3916],{"intervention":3633,"totalTrials":103,"cells":3990},{"EARLY_PHASE1":3991,"PHASE1":3993,"PHASE2":3995,"PHASE3":3997,"PHASE4":3999,"NA":4001},{"trials":3992,"activeCount":62},[],{"trials":3994,"activeCount":62},[],{"trials":3996,"activeCount":62},[],{"trials":3998,"activeCount":62},[],{"trials":4000,"activeCount":62},[],{"trials":4002,"activeCount":62},[4003],{"nctId":3626,"briefTitle":3627,"status":680,"phases":4004,"primaryCompletion":3629,"completion":3629,"start":3630,"enrollment":62,"conditions":4005,"interventions":4006},[55],[20],[3633,3634,524],{"intervention":3634,"totalTrials":103,"cells":4008},{"EARLY_PHASE1":4009,"PHASE1":4011,"PHASE2":4013,"PHASE3":4015,"PHASE4":4017,"NA":4019},{"trials":4010,"activeCount":62},[],{"trials":4012,"activeCount":62},[],{"trials":4014,"activeCount":62},[],{"trials":4016,"activeCount":62},[],{"trials":4018,"activeCount":62},[],{"trials":4020,"activeCount":62},[4021],{"nctId":3626,"briefTitle":3627,"status":680,"phases":4022,"primaryCompletion":3629,"completion":3629,"start":3630,"enrollment":62,"conditions":4023,"interventions":4024},[55],[20],[3633,3634,524],{"intervention":4026,"totalTrials":103,"cells":4027},"Definity",{"EARLY_PHASE1":4028,"PHASE1":4030,"PHASE2":4032,"PHASE3":4034,"PHASE4":4036,"NA":4038},{"trials":4029,"activeCount":62},[],{"trials":4031,"activeCount":62},[],{"trials":4033,"activeCount":62},[],{"trials":4035,"activeCount":62},[],{"trials":4037,"activeCount":62},[],{"trials":4039,"activeCount":62},[4040],{"nctId":4041,"briefTitle":4042,"status":68,"phases":4043,"primaryCompletion":4044,"completion":4044,"start":4045,"enrollment":671,"conditions":4046,"interventions":4047},"NCT02115607","Subharmonic Imaging and Pressure Estimation for Monitoring Neoadjuvant Chemotherapy",[55],"2018-05-23","2014-03",[18],[4026]]